View Filing Data

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2019	Aug. 01, 2019
Document and Entity Information
Document Type	10-Q
Document Period End Date	Jun. 30, 2019
Amendment Flag	false
Entity Registrant Name	Onconova Therapeutics, Inc.
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		5,998,524
Entity Central Index Key	0001130598
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q2

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 5,882	$ 16,970
Receivables	1,714	35
Prepaid expenses and other current assets	833	760
Total current assets	8,429	17,765
Property and equipment, net	1	9
Other non-current assets	150	149
Total assets	8,580	17,923
Current liabilities:
Accounts payable	4,750	4,039
Accrued expenses and other current liabilities	3,770	4,173
Deferred revenue	226	226
Total current liabilities	8,746	8,438
Warrant liability	571	176
Deferred revenue, non-current	3,809	3,922
Total liabilities	13,126	12,536
Commitments and contingencies
Stockholders' (deficit) equity:
Preferred stock, $0.01 par value, 5,000,000 authorized at June 30, 2019 and December 31, 2018, none issued and outstanding at June 30, 2019 and December 31, 2018
Common stock, $0.01 par value, 250,000,000 authorized at June 30, 2019 and December 31, 2018, 5,998,524 and 5,674,220 shares issued and outstanding at June 30, 2019 and December 31, 2018	60	57
Additional paid in capital	388,465	387,238
Accumulated other comprehensive loss	(14)	(12)
Accumulated deficit	(393,057)	(381,896)
Total Onconova Therapeutics, Inc. stockholders' (deficit) equity	(4,546)	5,387
Total stockholders' (deficit) equity	(4,546)	5,387
Total liabilities and stockholders' (deficit) equity	$ 8,580	$ 17,923

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2019	Dec. 31, 2018
Condensed Consolidated Balance Sheets
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	5,998,524	5,674,220
Common stock, shares outstanding	5,998,524	5,674,220

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Condensed Consolidated Statements of Operations
Revenue	$ 2,022	$ 485	$ 2,090	$ 1,049
Operating expenses:
General and administrative	1,760	2,054	4,994	3,943
Research and development	3,895	4,070	7,969	8,647
Total operating expenses	5,655	6,124	12,963	12,590
Loss from operations	(3,633)	(5,639)	(10,873)	(11,541)
Gain on dissolution of GBO		693		693
Change in fair value of warrant liability	32	513	(395)	1,325
Other income, net	40	112	107	112
Net loss	(3,561)	(4,321)	(11,161)	(9,411)
Net loss attributable to non-controlling interest		(163)		(163)
Net loss attributable to Onconova Therapeutics, Inc	$ (3,561)	$ (4,484)	$ (11,161)	$ (9,574)
Net loss per share, basic and diluted	$ (0.60)	$ (1.10)	$ (1.89)	$ (3.76)
Basic and diluted weighted average shares outstanding (in shares)	5,948,471	4,070,405	5,919,446	2,548,281

Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Condensed Consolidated Statements of Comprehensive Loss
Net loss	$ (3,561)	$ (4,321)	$ (11,161)	$ (9,411)
Other comprehensive income (loss), before tax:
Foreign currency translation adjustments, net	4	(16)	(2)	(8)
Other comprehensive income (loss), net of tax	4	(16)	(2)	(8)
Comprehensive loss	(3,557)	(4,337)	(11,163)	(9,419)
Comprehensive loss attributable to non-controlling interest		(163)		(163)
Comprehensive loss attributable to Onconova Therapeutics, Inc	$ (3,557)	$ (4,500)	$ (11,163)	$ (9,582)

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=84234705&loc=SL4591551-111686

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3000-108585

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=84234705&loc=SL4591552-111686

+ Details

Consolidated Statement of Stockholders' (Deficit) Equity - USD ($) $ in Thousands	Common Stock	Additional Paid in Capital	Accumulated deficit	Accumulated other comprehensive income (loss)	Non-controlling interest	Total
Balance at Dec. 31, 2017	$ 7	$ 350,615	$ (362,316)	$ 3	$ 830	$ (10,861)
Balance (in shares) at Dec. 31, 2017	718,078
Increase (Decrease) in Stockholders' Equity (Deficit)
Net loss			(9,574)		163	(9,411)
Other comprehensive income (loss)				(8)		(8)
Stock-based compensation		538				538
Issuance of common stock upon exercise of warrants	$ 7	582				589
Issuance of common stock upon exercise of warrants (in shares)	740,460
Dissolution of GBO			993		(993)
Issuance of common stock and pre-funded warrants, net	$ 42	35,026				35,068
Issuance of common stock and pre-funded warrants, net (in shares)	4,215,580
Balance at Jun. 30, 2018	$ 56	386,761	(370,897)	(5)		15,915
Balance (in shares) at Jun. 30, 2018	5,674,118
Balance at Mar. 31, 2018	$ 13	359,677	(367,406)	11	830	(6,875)
Balance (in shares) at Mar. 31, 2018	1,295,078
Increase (Decrease) in Stockholders' Equity (Deficit)
Net loss			(4,484)		163	(4,321)
Other comprehensive income (loss)				(16)		(16)
Stock-based compensation		211				211
Issuance of common stock upon exercise of warrants	$ 6	567				573
Issuance of common stock upon exercise of warrants (in shares)	630,460
Dissolution of GBO			993		$ (993)
Issuance of common stock and pre-funded warrants, net	$ 37	26,306				26,343
Issuance of common stock and pre-funded warrants, net (in shares)	3,748,580
Balance at Jun. 30, 2018	$ 56	386,761	(370,897)	(5)		15,915
Balance (in shares) at Jun. 30, 2018	5,674,118
Balance at Dec. 31, 2018	$ 57	387,238	(381,896)	(12)		$ 5,387
Balance (in shares) at Dec. 31, 2018	5,674,220					5,674,220
Increase (Decrease) in Stockholders' Equity (Deficit)
Net loss			(11,161)			$ (11,161)
Other comprehensive income (loss)				(2)		(2)
Stock-based compensation		805				805
Issuance of common stock	$ 1	391				392
Issuance of common stock (in shares)	103,520
Issuance of common stock upon exercise of warrants	$ 2	31				33
Issuance of common stock upon exercise of warrants (in shares)	220,784
Balance at Jun. 30, 2019	$ 60	388,465	(393,057)	(14)		$ (4,546)
Balance (in shares) at Jun. 30, 2019	5,998,524					5,998,524
Balance at Mar. 31, 2019	$ 59	387,919	(389,496)	(18)		$ (1,536)
Balance (in shares) at Mar. 31, 2019	5,895,004
Increase (Decrease) in Stockholders' Equity (Deficit)
Net loss			(3,561)			(3,561)
Other comprehensive income (loss)				4		4
Stock-based compensation		155				155
Issuance of common stock	$ 1	391				392
Issuance of common stock (in shares)	103,520
Balance at Jun. 30, 2019	$ 60	$ 388,465	$ (393,057)	$ (14)		$ (4,546)
Balance (in shares) at Jun. 30, 2019	5,998,524					5,998,524

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Operating activities:
Net loss	$ (11,161)	$ (9,411)
Adjustment to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	8	30
Change in fair value of warrant liabilities	395	(1,325)
Stock compensation expense	805	538
Gain on dissolution of GBO		(693)
Changes in assets and liabilities:
Receivables	(1,679)	(13)
Prepaid expenses and other current assets	(73)	275
Accounts payable	711	456
Accrued expenses and other current liabilities	(403)	237
Deferred revenue	(113)	(227)
Net cash used in operating activities	(11,510)	(10,133)
Financing activities:
Proceeds from the sale of common stock and warrants, net of costs	391	35,068
Proceeds from the exercise of warrants	33	589
Net cash provided by financing activities	424	35,657
Effect of foreign currency translation on cash	(2)	(8)
Net (decrease) increase in cash and cash equivalents	(11,088)	25,516
Cash and cash equivalents at beginning of period	16,970	4,024
Cash and cash equivalents at end of period	$ 5,882	$ 29,540

Nature of Business	6 Months Ended
Nature of Business	Jun. 30, 2019
Nature of Business
Nature of Business	1. Nature of Business Reverse Stock Split All common stock, equity, share and per share amounts in the financial statements and notes have been retroactively adjusted to reflect a one-for-fifteen reverse stock split which was effective September 25, 2018. The Company Onconova Therapeutics, Inc. (the “Company”) was incorporated in the State of Delaware on December 22, 1998 and commenced operations on January 1, 1999. The Company’s headquarters are located in Newtown, Pennsylvania. The Company is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule product candidates primarily to treat cancer. Using its proprietary chemistry platform, the Company has created an extensive library of targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells. The Company believes that the product candidates in its pipeline have the potential to be efficacious in a variety of cancers. The Company has three clinical-stage product candidates and several preclinical programs. In 2011, the Company entered into a license agreement, as subsequently amended, with SymBio Pharmaceuticals Limited (“SymBio”), which grants SymBio certain rights to commercialize rigosertib in Japan and Korea. On March 2, 2018, the Company entered into a License, Development and Commercialization Agreement with Pint International SA (which, together with its affiliate Pint Pharma GmbH, are collectively referred to as “Pint”). Under the terms of the agreement, the Company granted Pint an exclusive, royalty-bearing license, with the right to sublicense, under certain Company patent rights and know-how to develop and commercialize any pharmaceutical product containing rigosertib in all uses of rigosertib in certain Latin America countries. In 2012, the Company entered into a development and license agreement with Baxter Healthcare SA, the predecessor in interest to Baxalta GmbH (together with its affiliates, “Baxalta”), pursuant to which the Company granted an exclusive, royalty-bearing license for the research, development, commercialization and manufacture (in specified instances) of rigosertib in all therapeutic indications in Europe. The Baxalta agreement terminated effective August 30, 2016, at which time the rights the Company licensed to Baxalta reverted to the Company at no cost. The Company has retained development and commercialization rights to rigosertib in the rest of the world, including the United States. During 2012, Onconova Europe GmbH was established as a wholly owned subsidiary of the Company for the purpose of further developing business in Europe. In December 2017, the Company entered into a license and collaboration agreement with HanX Biopharmaceuticals, Inc. (“HanX”), a company focused on development of novel oncology products, for the further development, registration and commercialization of ON 123300 in Greater China. ON 123300 is a preclinical compound which the Company believes has the potential to overcome the limitations of current generation CDK 4/6 inhibitors. The key feature of the collaboration is that HanX will provide all funding required for future Chinese IND enabling studies necessary for filing an IND with the Chinese Food and Drug Administration. The studies would be conducted to meet the Good Laboratory Practice (“GLP”) requirements of the FDA such that the Company could simultaneously file an IND with the US FDA. The Company and HanX will oversee the IND enabling studies. The Company will maintain global rights to ON 123300 outside of China. In April 2013, GBO, LLC, a Delaware limited liability company, (“GBO”) was formed pursuant to an agreement with GVK Biosciences Private Limited, a private limited company located in India, (“GVK”) to collaborate and develop two programs using the Company’s technology platform. The two preclinical programs sublicensed to GBO were not developed to clinical stage as initially hoped, and GBO was dissolved in June 2018. In May 2019, the Company entered into a License and Collaboration Agreement with HanX to study and commercialize rigosertib in greater China. On March 21, 2018, the Company amended its certificate of incorporation to increase the number of authorized shares of common stock par value $0.01 per share from 25,000,000 to 100,000,000. On June 7, 2018, the Company amended its certificate of incorporation again to increase the number of authorized shares of common stock, par value $0.01 per share, from 100,000,000 to 250,000,000. On September 25, 2018, the Company amended its certificate of incorporation to effect a one-for-fifteen reverse stock split of its common stock. Liquidity The Company has incurred recurring operating losses since inception. For the six months ended June 30, 2019, the Company incurred a net loss of $11,161,000 and as of June 30, 2019 the Company had generated an accumulated deficit of $393,057,000. The Company anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to research, development of its product candidates and its preclinical programs, strategic alliances and its administrative organization. At June 30, 2019, the Company had cash and cash equivalents of $5,882,000. The Company will require substantial additional financing to fund its ongoing clinical trials and operations, and to continue to execute its strategy. These conditions raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the financial statements are issued. From its inception through July 2013, the Company raised capital through the private issuance of preferred stock. On July 30, 2013, the Company completed its initial public offering (the “IPO”) of 39,611 shares of Common Stock, at a price of $2,250.00 per share. The Company received net proceeds of $79,811,000 from the sale, net of underwriting discounts and commissions and other estimated offering expenses. Immediately prior to the consummation of the IPO, all outstanding shares of preferred stock automatically converted into shares of Common Stock at the applicable conversion ratio then in effect. From the IPO through December 31, 2016, the Company closed on several offerings which included Common Stock and warrants. Total net proceeds from these offerings was approximately $24.9 million. On April 26, 2017 the Company closed on an underwritten public offering of 165,079 shares of Common Stock. On May 17, 2017, the Company sold an additional 24,239 shares as a result of the underwriter’s exercise of its over-allotment option. Net proceeds from these transactions were approximately $5.3 million. On November 14, 2017 the Company closed on a registered direct offering to select accredited investors of 61,333 shares of common stock. Net proceeds were approximately $1.1 million. On February 12, 2018 the Company closed on an offering of units of common stock and warrants. The Company issued 467,000 shares of common stock, pre-funded warrants to purchase 196,167 share of common stock, and preferred stock warrants to purchase shares of Series A convertible preferred stock convertible into 696,325 shares of common stock. Net proceeds were approximately $8.7 million. (See Note 13) On May 1, 2018 the Company closed on an offering of units of common stock and warrants. The Company issued 3,694,118 shares of common stock, pre-funded warrants to purchase 815,686 shares of common stock, and preferred stock warrants to purchase shares of Series B convertible preferred stock convertible into 4,509,804 shares of common stock. Net proceeds were approximately $25.6 million. (See Note 13) In February and March 2019 the Company implemented a workforce reduction. Six employees were terminated, which represented approximately 24% of the Company’s workforce. A severance related charge of approximately $1,843,000, which includes a non-cash charge of approximately $415,000 related to the accelerated vesting of outstanding stock options, was recorded in the three months ended March 31, 2019. The severance expense will be paid in periodic amounts through February 2020. The accrued severance balance remaining at June 30, 2019 was $810,000. On May 10, 2019, the Company entered into a License and Collaboration Agreement (the “HanX License Agreement”) with HanX and two Securities Purchase Agreements (the “HanX Securities Purchase Agreements"), one with HanX and the other with an affiliate of HanX. Under the terms of the agreements, the Company granted to HanX an exclusive, royalty bearing license to study and commercialize rigosertib in greater China. In exchange for these rights, HanX agreed to make upfront payments to the Company totaling $4 million, including a $2 million fee and an investment totaling $2 million to purchase shares of the Company at a premium to market. In addition, HanX agreed to dedicate $2 million in local currency, to be placed in escrow, for clinical development expenses in greater China. In addition, the Company could receive regulatory, development and sales-based milestone payments to Onconova of up to $45.5 million and receive tiered royalties up to double digits on net sales in greater China. The Company will supply the finished product for sale in the licensed territories. HanX will also support the Company’s clinical trial initiatives in the territory. On July 9, 2019, the Company extended the deadline for payments under the HanX License Agreement and the HanX Securities Purchase Agreements. On August 8, 2019 Onconova received the non-refundable license fee from HanX. On August 14, 2019, the Company further extended the deadline of HanX’ remaining upfront payments relating to the its equity investment in the Company while HanX continues to seek Chinese regulatory approval for such equity investment. See Note 10 for additional information. The Company has and may continue to delay, scale-back, or eliminate certain of its research and development activities and other aspects of its operations until such time as the Company is successful in securing additional funding. The Company continues to explore various dilutive and non-dilutive sources of funding, including equity financings, strategic alliances, business development and other sources. The future success of the Company is dependent upon its ability to obtain additional funding. There can be no assurance, however, that the Company will be successful in obtaining such funding in sufficient amounts, on terms acceptable to the Company, or at all. The Company currently anticipates that current cash and cash equivalents will be sufficient to meet its anticipated cash requirements into the fourth quarter of 2019. Accordingly, management has concluded that substantial doubt exists with respect to the Company's ability to continue as a going concern within one year after the date that these financial statements are issued.

Summary of Significant Accounting Policies	6 Months Ended
Summary of Significant Accounting Policies	Jun. 30, 2019
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The condensed consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States (“GAAP”) for interim financial information. Certain information and footnotes normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). The financial statements include the consolidated accounts of the Company, its wholly-owned subsidiary, Onconova Europe GmbH, and GBO (through the date of its dissolution in June 2018). All significant intercompany transactions have been eliminated. Unaudited Interim Financial Information The accompanying condensed consolidated balance sheet as of June 30, 2019, the condensed consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2019 and 2018, the consolidated statements of stockholders’ (deficit) equity for the three and six months ended June 30, 2019 and 2018 and the condensed consolidated statements of cash flows for the six months ended June 30, 2019 and 2018 are unaudited. The interim unaudited condensed consolidated financial statements have been prepared on the same basis as the annual audited consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the Company’s financial position as of June 30, 2019, the results of its operations for the three and six months ended June 30, 2019 and 2018, and its cash flows for the six months ended June 30, 2019 and 2018. The financial data and other information disclosed in these notes related to the three and six months ended June 30, 2019 and 2018 are unaudited. The results for the three and six months ended June 30, 2019 are not necessarily indicative of results to be expected for the year ending December 31, 2019, any other interim periods, or any future year or period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto for the year ended December 31, 2018 included in the Company’s annual report on Form 10-K filed with the SEC on April 1, 2019. Certain prior year amounts have been reclassified to conform to current period presentation. All common stock, equity, share and per share amounts in the financial statements and notes have been retroactively adjusted to reflect a one-for-fifteen reverse stock split which was effective September 25, 2018. Segment Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one segment, which is the identification and development of oncology therapeutics. Significant Accounting Policies The Company’s significant accounting policies are disclosed in the audited consolidated financial statements for the year ended December 31, 2018 included in the Company’s annual report on Form 10-K filed with the SEC on April 1, 2019. Since the date of such financial statements, there have been no changes to the Company’s significant accounting policies, with the exception of the adoption of new FASB guidance related to leases. Fair Value Measurements The carrying amounts reported in the accompanying consolidated financial statements for cash and cash equivalents, accounts payable, and accrued liabilities approximate their respective fair values because of the short-term nature of these accounts. The fair value of the warrant liability is discussed in Note 7, “Fair Value Measurements.” Revenue Recognition The Company recognizes revenue in accordance with Accounting Standards Codification Topic 606, Revenue from Contracts with Customers (ASC 606), which the Company adopted effective January 1, 2018 using the modified retrospective method. There was no material impact to our financial position and results of operations as a result of the adoption. The Company applies ASC 606 to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. In accordance with ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that it will collect the consideration it is entitled to in exchange for the goods and services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract that falls under the scope of ASC 606, determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. The Company derives revenue from collaboration and licensing agreements and from the sale of products associated with material transfer, collaboration and supply agreements. License, Collaboration and Other Revenues The Company enters into licensing and collaboration agreements, under which it licenses certain of its product candidates’ rights to third parties. The Company recognizes revenue related to these agreements in accordance with ASC 606. The terms of these arrangements typically include payment from third parties of one or more of the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments; and royalties on net sales of the licensed product. In determining the appropriate amount of revenue to be recognized as it fulfills its obligation under each of its agreements, the Company performs the five steps described above. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement of personnel costs, discount rates and probabilities of technical and regulatory success. Licensing of Intellectual Property: If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other performance obligations, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front-fees. The Company evaluates the measure of progress each reporting period, and, if necessary, adjusts the measure of performance and related revenue recognition. Milestone Payments: At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal will not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensees, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in their period of adjustment. Manufacturing supply services. Arrangements that include a promise for future supply of drug substance or drug product for either clinical development or commercial supply at the customer’s discretion are generally considered as options. The Company assesses if these options provide material rights to the licensee and if so, they are accounted for as separate performance obligations. If the Company is entitled to additional payments when the customer exercises these options, any additional payments are recorded when the customer obtains control of the goods, which is upon shipment. Royalties: For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some of all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue from its license agreements. Leases The Company accounts for leases in accordance with Accounting Standards Codification Topic 842, Leases (ASC 842), which the Company adopted effective January 1, 2019. The Company determines whether an arrangement is a lease at contract inception by establishing if the contract conveys the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. Right of Use (ROU) Assets and Lease Liabilities are recognized at the lease commencement date based on the present value of all minimum lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments, when the implicit rate is not readily determinable. Lease terms may include options to extend or terminate the lease. These options are included in the lease term when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has elected the following policy elections on adoption: use of portfolio approach on leases of assets under master service agreements, exclusion of short term leases (term of 12 months or less) on the balance sheet, and not separating lease and non-lease components. At January 1, 2019 and June 30, 2019 the Company had one lease, which was for office space. The lease qualifies for the short term lease exception. Consequently, no ROU Asset or Lease Liability was recorded. The lease payments are being recognized as an expense on a straight-line basis over the lease term. Lease payments for the six months ended June 30, 2019 were $96,000. Remaining payments due under the lease at June 30, 2019 are $129,000. Recent Accounting Pronouncements In February 2016 and through subsequent amendments, the FASB issued guidance which supersedes much of the previous guidance for leases. The new guidance requires lessees to recognize a right-of-use asset and a lease liability on their balance sheets for all the leases with terms greater than twelve months. Based on certain criteria, leases are classified as either financing or operating, with classification affecting the pattern of expense recognition in the income statement. For leases with a term of twelve months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. If a lessee makes this election, it should recognize lease expense for such leases generally on a straight-line basis over the lease term. The guidance was effective for fiscal years beginning after December 15, 2018, and interim periods within those years, with early adoption permitted. In transition, lessees and lessors were permitted to recognize and measure leases at the date of adoption using a modified retrospective approach. The modified retrospective approach includes a number of optional practical expedients primarily focused on leases that commenced before the effective date of the new guidance, including continuing to account for leases that commence before the effective date in accordance with previous guidance, unless the lease is modified. The Company adopted the guidance in ASC 842 effective January 1, 2019 using the modified retrospective method, which does not require the restatement of prior period amounts. There was no impact to the Company’s financial position and results of operations as a result of the adoption. In August 2018, the FASB issued guidance which changes the disclosure requirements for fair value measurement. The guidance amends the disclosure requirements in ASC Topic 820 by adding, changing, or removing certain disclosures. The guidance is effective for fiscal years beginning after December 15, 2019. The Company believes that the adoption of this guidance will not have a material impact on the Company’s consolidated financial statements. The Company is evaluating the impact of the adoption of the standard on its financial statement disclosures. In November 2018, the FASB issued guidance, which clarifies the interaction between ASC Topic 808, Collaborative Arrangements, and ASC Topic 606, Revenue from Contracts with Customers. The guidance, among other items, clarifies that certain transactions between collaborative participants should be accounted for as revenue under Topic 606 when the collaborative arrangement participant is a customer in the context of a unit of account. The guidance is effective for fiscal years beginning after December 15, 2019. The Company is evaluating the impact that the adoption of this guidance will have on the Company’s consolidated financial statements.

Revenue

6 Months Ended

Jun. 30, 2019

Revenue

Revenue

3. Revenue

The Company’s revenue during the three and six months ended June 30, 2019 and 2018 was from its license and collaboration agreements with SymBio, HanX and Pint (See Note 10).


	Three Months Ended June 30,				Six Months Ended June 30,
	2019		2018		2019		2018

Symbio
Upfront license fee recognition over time	$	56,000	$	113,000	$	113,000	$	227,000
Supplies		1,000		53,000		12,000		53,000

HanX - rigosertib
Upfront license payment		1,965,000		—		1,965,000		—

HanX - ON123300
Upfront license payment		—		—		—		450,000

Pint
Upfront license payment		—		319,000		—		319,000

	$	2,022,000	$	485,000	$	2,090,000	$	1,049,000

Deferred revenue is as follows:


	Symbio
	Upfront Payment

Deferred balance at December 31, 2018	$	4,148,000
Recognition to revenue		113,000

Deferred balance at June 30, 2019	$	4,035,000

See Note 10, “License and Collaboration Agreements,” for a further discussion of the agreements with SymBio and HanX.

Warrants

6 Months Ended

Jun. 30, 2019

Warrants

Warrants

5. Warrants

Common Stock warrants are accounted for in accordance with applicable accounting guidance provided in ASC Topic 815, Derivatives and Hedging - Contracts in Entity’s Own Equity (ASC Topic 815), as either derivative liabilities or as equity instruments depending on the specific terms of the warrant agreement. Some of the Company’s warrants are classified as liabilities because in certain circumstances they could require cash settlement.

Warrants outstanding and warrant activity (reflects the number of common shares as if the warrants were converted to common stock) for the six months ended June 30, 2019 is as follows:


					Balance				Balance
		Exercise		Expiration	Decemeber 31,	Warrants	Warrants	Warrants	June 30,
Description	Classification	Price		Date	2018	Issued	Exercised	Expired	2019

Non-tradable warrants	Liability	$	172.50	July 2021	6,456	—	—	—	6,456
Tradable warrants	Liability	$	73.80	July 2021	212,801	—	—	—	212,801
Non-tradable pre-funded warrants	Equity	$	0.15	July 2023	394	—	—	—	394
Non-tradable warrants	Equity	$	6.69375	*	663,167	—	—	—	663,167
Non-tradable warrants	Equity	$	7.96875	*	33,158	—	—	—	33,158
Non-tradable warrants	Equity	$	14.10	March 2021	5,000	—	—	—	5,000
Non-tradable warrants	Equity	$	21.15	March 2021	8,333	—	—	—	8,333
Non-tradable warrants	Equity	$	7.7895	June 2021	15,000	—	—	—	15,000
Non-tradable pre-funded warrants	Equity	$	0.15	none	86,167	—	(33,333)	—	52,834
Non-tradable warrants	Equity	$	6.375	**	4,432,962	—	—	—	4,432,962
Non-tradable pre-funded warrants	Equity	$	0.15	none	262,068	—	(187,451)	—	74,617

					5,725,506	—	(220,784)	—	5,504,722

* These preferred stock warrants expire on the earlier of (A) the one-month anniversary of the date on which the Company publically releases topline results of the INSPIRE Pivotal phase 3 that compare the overall survival (OS) of patients in the rigosertib group vs the Physician's Choice group, in all patients and in a subgroup of patients with IPSS-R very high risk and (B) December 31, 2019. These preferred stock warrants may be exercised on a cashless basis in certain circumstances specified therein.

** These preferred stock warrants expire on the 18-month anniversary of June 8, 2018, the date on which the Company publicly announced through the filing of a Current Report on Form 8-K that a Certificate of Amendment to the Company's Tenth Amended and Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of common stock from 100,000,000 to 250,000,000, was filed with the Secretary of State of the State of Delaware. These preferred stock warrants may be exercised on a cashless basis in certain circumstances specified therein.

Balance Sheet Detail

6 Months Ended

Jun. 30, 2019

Balance Sheet Detail

Balance Sheet Detail

6. Balance Sheet Detail

Receivables:


	June 30,		December 31,
	2019		2018

Amounts due from HanX	$	1,679,000	$	—
Other		35,000		35,000
	$	1,714,000	$	35,000

Prepaid expenses and other current assets:


	June 30,		December 31,
	2019		2018

Research and development	$	433,000	$	415,000
Premium on future equity purchase from HanX		214,000		—
Manufacturing		33,000		111,000
Insurance		62,000		166,000
Other		91,000		68,000
	$	833,000	$	760,000

Property and equipment:


	June 30,		December 31,
	2019		2018

Property and equipment	$	2,228,000	$	2,228,000
Accumulated depreciation		(2,227,000)		(2,219,000)
	$	1,000	$	9,000

Accrued expenses and other current liabilities:


	June 30,		December 31,
	2019		2018

Research and development	$	2,103,000	$	2,285,000
Employee compensation		1,510,000		1,650,000
Professional fees		157,000		225,000
Other		—		13,000
	$	3,770,000	$	4,173,000

Fair Value Measurements

6 Months Ended

Jun. 30, 2019

Fair Value Measurements

Fair Value Measurements

7. Fair Value Measurements

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.

The Company utilizes a valuation hierarchy for disclosure of the inputs to the valuations used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on the Company’s own assumptions used to measure assets and liabilities at fair value. A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement.

On January 5, 2016, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with an institutional investor providing for the issuance and sale by the Company of 12,912 shares of Common Stock, at a purchase price of $142.50 per share and warrants to purchase up to 6,456 shares of Common Stock (the “Warrants”) for aggregate gross proceeds of $1,840,000. The Company has classified the warrants as a liability (see Note 5). The estimated fair value using the Black-Scholes pricing model was approximately $0 at June 30, 2019 and December 31, 2018.

On July 29, 2016 the Company closed on a Rights Offering, issuing 239,986 shares of Common Stock, 212,801 Tradable Warrants and 43,760 Pre-Funded Warrants. The Tradable Warrants are exercisable for a period of five years for one share of Common Stock at an exercise price of $73.80 per share. After the one-year anniversary of issuance, the Company may redeem the Tradable Warrants for $0.001 per Tradable Warrant if the volume weighted average price of its Common Stock is above $184.50 for each of 10 consecutive trading days. The Company has classified the Tradable Warrants as a liability (see Note 5). The Tradable Warrants have been listed on the Nasdaq Capital Market since issuance and the Company regularly monitors the trading activity. The Company has determined that an active and orderly market for the Tradable Warrants has developed and that the Nasdaq Capital Market price is the best indicator of fair value of the warrant liability. The quoted market price was used to determine the fair value at December 31, 2018 and June 30, 2019.

The Company estimated the fair value of the non-tradable warrant liability at June 30, 2019, using the Black-Scholes option pricing model with the following weighted-average assumptions:


Risk-free interest rate	1.75	%
Expected volatility	82.96	%
Expected term	2.04 years
Expected dividend yield	0	%

Expected volatility is based on the historical volatility of the Company’s Common Stock since its IPO in July 2013.

The following fair value hierarchy table presents information about the Company’s financial assets and liabilities measured at fair value on a recurring basis as of June 30, 2019 and December 31, 2018:


	Fair Value Measurement as of:
	June 30, 2019								December 31, 2018
	Level 1		Level 2		Level 3		Balance		Level 1		Level 2		Level 3		Balance

Tradable warrants liability	$	571,000	$	—	$	—	$	571,000	$	176,000	$	—	$	—	$	176,000
Non-tradable warrants liability		—		—		—		—		—		—		—		—
Total	$	571,000	$	—	$	—	$	571,000	$	176,000	$	—	$	—	$	176,000

There were no transfers between Level 1 and Level 2 in any of the periods reported.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Stock-Based Compensation

6 Months Ended

Jun. 30, 2019

Stock-Based Compensation

Stock-Based Compensation

8. Stock-Based Compensation

The 2007 Equity Compensation Plan as amended (the “2007 Plan”), amended, restated and renamed the Company’s 1999 Stock Based Compensation Plan (the “1999 Plan”), which provided for the granting of incentive and nonqualified stock options and restricted stock to its employees, directors and consultants at the discretion of the board of directors.

The 2013 Equity Compensation Plan (the “2013 Plan”), amended, restated and renamed the 2007 Plan. Under the 2013 Plan, the Company may grant incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units, deferred share awards, performance awards and other equity-based awards to employees, directors and consultants. The Company initially reserved 610,783 shares of Common Stock for issuance, subject to adjustment as set forth in the 2013 Plan. The 2013 Plan included an evergreen provision, pursuant to which the maximum aggregate number of shares that may be issued under the 2013 Plan is increased on the first day of each fiscal year by the lesser of (a) a number of shares equal to four percent (4%) of the issued and outstanding Common Stock of the Company, without duplication, (b) 200,000 shares and (c) such lesser number as determined by the Company’s board of directors, subject to specified limitations.

The 2018 Omnibus Incentive Compensation Plan (the “2018 Plan”) was unanimously approved by the Company’s Board of Directors on May 24, 2018 and was approved by the Company’s stockholders on June 27, 2018. The 2018 Plan replaces the 2013 Plan. Upon stockholders’ approval of the 2018 Plan, no further awards will be made under the 2013 Plan. Awards granted under the 2013 Plan will continue in effect in accordance with the terms of the applicable award agreement and the terms of the 2013 Plan in effect when the awards were granted.

Under the 2018 Plan, the Company may grant incentive stock options, non-qualified stock options, stock awards, stock units, stock appreciation rights and other stock-based awards to employees, non-employee directors and consultants, and advisors. The maximum aggregate number of shares of the Company’s common stock that may be issued under the 2018 Plan is 6,035,316, which is equal to the sum of (i) 6,000,000 shares of the Company’s common stock, plus (ii) 35,316 shares, which is the number of shares of the Company common stock reserved for issuance under the 2013 Plan that remained available as of the effective date of the 2018 Plan. In addition, the number of shares of common stock subject to outstanding awards under the 2013 Plan that terminate, expire, or are cancelled, forfeited, exchanged, or surrendered without having been exercised, vested, or paid in shares under the 2013 Plan after the effective date of the 2018 Plan will be available for issuance under the 2018 Plan.

The 2018 Plan was amended following unanimous approval of the Company's Board of Directors on April 24, 2019 and was approved by the Company's shareholders on June 17, 2019. The amended 2018 Plan (the "Amended Plan") allowed for an additional 589,500 shares of the Company's common stock that may be issued under the Amended Plan with respect to awards made on and after June 17, 2019. At June 30, 2019, there were 698,390 shares available for future issuance.

Stock-based compensation expense includes stock options granted to employees and non-employees and has been reported in the Company’s statements of operations and comprehensive loss in either research and development expenses or general and administrative expenses depending on the function performed by the optionee. No net tax benefits related to the stock-based compensation costs have been recognized since the Company’s inception. The Company recognized stock-based compensation expense as follows for the three and six months ended June 30, 2019 and 2018:


	Three Months ended June 30,				Six Months ended June 30,
	2019		2018		2019		2018
General and administrative	$	67,000	$	109,000	$	606,000	$	227,000
Research and development		88,000		102,000		199,000		261,000
	$	155,000	$	211,000	$	805,000	$	488,000

A summary of stock option activity for the six months ended June 30, 2019 is as follows:


		Options Outstanding
					Weighted
			Weighted-		Average
	Shares		Average		Remaining	Aggregate
	Available	Number of	Exercise		Contractual	Intrinsic
	for Grant	Shares	Price		Term (in years)	Value
Balance, December 31, 2018	95,264	379,328	$	76.33	9.19	$	0
Authorized	589,500	—
Granted	(10,000)	10,000	$	3.72	9.75
Exercised	—	—	$	—
Forfeitures	23,626	(33,534)	$	61.68	8.92
Balance, June 30, 2019	698,390	355,794	$	75.67	8.70	$	0
Vested or expected to vest, June 30, 2019		346,507	$	192.66	7.93	$	0
Exercisable at June 30, 2019		131,468	$	192.66	7.93	$	0

Information with respect to stock options outstanding and exercisable at June 30, 2019 is as follows:


Exercise Price	Shares	Exercisable
$3.41 – $7.05	288,246	71,040
$16.35 – $97.50	48,133	41,090
$222.00 – $225.00	1,871	1,811
$348.00 – $597.00	4,867	4,863
$651.00 – $1,129.50	5,432	5,419
$1,992.00 – $2,268.00	6,910	6,910
$4,156.50 – $4,371.00	335	335
	355,794	131,468

The Company uses the Black-Scholes option-pricing model to estimate the fair value of stock options at the grant date. The Black-Scholes model requires the Company to make certain estimates and assumptions, including estimating the fair value of the Company’s Common Stock, assumptions related to the expected price volatility of the Common Stock, the period during which the options will be outstanding, the rate of return on risk-free investments and the expected dividend yield for the Company’s stock.

As of June 30, 2019, there was $793,000 of unrecognized compensation expense related to the unvested stock options issued from April 24, 2013 through June 30, 2019, which is expected to be recognized over a weighted-average period of approximately 2.32 years.

The weighted-average assumptions underlying the Black-Scholes calculation of grant date fair value include the following:


	Six Months ended June 30,
	2019			2018
Risk-free interest rate		1.82	%		2.60	%
Expected volatility		83.68	%		74.13	%
Expected term		6.25	years		5.78	years
Expected dividend yield		0	%		0	%
Weighted average grant date fair value	$	2.68		$	12.60

The weighted-average valuation assumptions were determined as follows:

Risk-free interest rate: The Company based the risk-free interest rate on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected option term.

Expected term of options: Due to its lack of sufficient historical data, the Company estimates the expected life of its employee stock options using the “simplified” method, as prescribed in Staff Accounting Bulletin (SAB) No. 107, whereby the expected life equals the arithmetic average of the vesting term and the original contractual term of the option.

Expected stock price volatility: Expected volatility is based on the historical volatility of the Company’s Common Stock since its IPO in July 2013.

Expected annual dividend yield: The Company has never paid, and does not expect to pay, dividends in the foreseeable future. Accordingly, the Company assumed an expected dividend yield of 0.0%.

Estimated forfeiture rate: The Company’s estimated annual forfeiture rate on stock option grants was 4.14% in 2019 and 2018, based on the historical forfeiture experience.

License and Collaboration Agreements	6 Months Ended
License and Collaboration Agreements	Jun. 30, 2019
License and Collaboration Agreements
License and Collaboration Agreements	10. License and Collaboration Agreements SymBio Agreement In July 2011, the Company entered into a license agreement with SymBio, which has been subsequently amended, granting SymBio an exclusive, royalty-bearing license for the development and commercialization of rigosertib in Japan and Korea. Under the SymBio license agreement, SymBio is obligated to use commercially reasonable efforts to develop and obtain market approval for rigosertib inside the licensed territory and the Company has similar obligations outside of the licensed territory. The Company has also entered into an agreement with SymBio providing for it to supply SymBio with development-stage product. Under the SymBio license agreement, the Company also agreed to supply commercial product to SymBio under specified terms that will be included in a commercial supply agreement to be negotiated prior to the first commercial sale of rigosertib. The supply of development-stage product and the supply of commercial product will be at the Company's cost plus a defined profit margin. Sales of development-stage product have been de minimis. The Company has additionally granted SymBio a right of first negotiation to license or obtain the rights to develop and commercialize compounds having a chemical structure similar to rigosertib in the licensed territory. Under the terms of the SymBio license agreement, the Company received an upfront payment of $7,500,000 in 2011. The Company is eligible to receive milestone payments of up to an aggregate of $22,000,000 from SymBio upon the achievement of specified development and regulatory milestones for specified indications. Of the regulatory milestones, $5,000,000 is due upon receipt of marketing approval in the United States for rigosertib IV in higher-risk MDS patients, $3,000,000 is due upon receipt of marketing approval in Japan for rigosertib IV in higher-risk MDS patients, $5,000,000 is due upon receipt of marketing approval in the United States for rigosertib oral in lower-risk MDS patients, and $5,000,000 is due upon receipt of marketing approval in Japan for rigosertib oral in lower-risk MDS patients. Furthermore, upon receipt of marketing approval in the United States and Japan for an additional specified indication of rigosertib, which the Company is currently not pursuing, an aggregate of $4,000,000 would be due. In addition to these pre-commercial milestones, the Company is eligible to receive tiered milestone payments based upon annual net sales of rigosertib by SymBio of up to an aggregate of $30,000,000. Further, under the terms of the SymBio license agreement, SymBio will make royalty payments to the Company at percentage rates ranging from the mid-teens to 20% based on net sales of rigosertib by SymBio. Royalties will be payable under the SymBio agreement on a country-by-country basis in the licensed territory, until the later of the expiration of marketing exclusivity in those countries, a specified period of time after first commercial sale of rigosertib in such country, or the expiration of all valid claims of the licensed patents covering rigosertib or the manufacture or use of rigosertib in such country. If no valid claim exists covering the composition of matter of rigosertib or the use of or treatment with rigosertib in a particular country before the expiration of the royalty term, and specified competing products achieve a specified market share percentage in such country, SymBio's obligation to pay the Company royalties will continue at a reduced royalty rate until the end of the royalty term. In addition, the applicable royalties payable to the Company may be reduced if SymBio is required to pay royalties to third-parties for licenses to intellectual property rights necessary to develop, use, manufacture or commercialize rigosertib in the licensed territory. The license agreement with SymBio will remain in effect until the expiration of the royalty term. However, the SymBio license agreement may be terminated earlier due to the uncured material breach or bankruptcy of a party, or force majeure. If SymBio terminates the license agreement in these circumstances, its licenses to rigosertib will survive, subject to SymBio's milestone and royalty obligations, which SymBio may elect to defer and offset against any damages that may be determined to be due from the Company. In addition, the Company may terminate the license agreement in the event that SymBio brings a challenge against it in relation to the licensed patents, and SymBio may terminate the license agreement without cause by providing the Company with written notice within a specified period of time in advance of termination. The Company assessed the SymBio arrangement in accordance with ASC 606 and determined that its performance obligations under the SymBio agreement include the exclusive, royalty-bearing, sublicensable license to rigosertib, the research and development services to be provided by the Company and its obligation to serve on a joint committee. The Company concluded that the license was not distinct since it was of no benefit to SymBio without the ongoing research and development services and that, as such, the license and the research and development services should be bundled as a single performance obligation. Since the provision of the license and research and development services are considered a single performance obligation, the $7,500,000 upfront payment is being recognized as revenue ratably through December 2037, the expected period over which the Company expects the research and development services to be performed as the services are performed. SymBio’s purchases of rigosertib as development-stage product or for commercial requirements represent options under the agreement and revenues are therefore recognized when control of the product is transferred, which is typically when shipped. If SymBio orders the supplies from the Company, the Company expects the pricing for this supply to equal its third-party manufacturing cost plus a pre-negotiated percentage, which will not result in a significant incremental discount to market rates. In January 2018, the agreement was amended to provide SymBio a discount of 35% on future purchases, limited to a cumulative total amount of $300,000. HanX ON 123300 Agreement In December 2017, the Company entered into a license and collaboration agreement with HanX, a company focused on development of novel oncology products, for the further development, registration and commercialization of ON 123300 in Greater China. ON 123300 is a preclinical compound which the Company believes has the potential to overcome the limitations of current generation CDK 4/6 inhibitors. The key feature of the collaboration is that HanX will provide all funding required for future Chinese IND enabling studies necessary for filing an IND with the Chinese Food and Drug Administration. The studies would be conducted to meet the Good Laboratory Practice (“GLP”) requirements of the FDA such that the Company could simultaneously file an IND with the US FDA. The Company and HanX will oversee the IND enabling studies. The Company will maintain global rights to ON 12330 outside of China. Pursuant to the agreement, the Company received a $450,000 upfront payment on April 11, 2018. If the compound receives regulatory approval and is commercialized, the Company would receive regulatory and commercial milestone payments, as well as royalties on sales in the Greater China territory. The Company assessed the HanX arrangement for revenue recognition in accordance with ASC 606 and determined that the license was distinct and that control of the license had been transferred during the first quarter of 2018. As such, the Company recognized the $450,000 allocated to the license in the quarter ended March 31, 2018. Pint Agreement On March 2, 2018, the Company entered into a License, Development and Commercialization Agreement (the “License Agreement”) and a Securities Purchase Agreement (the “Securities Purchase Agreement”) with Pint. Under the terms of the License Agreement, the Company granted Pint an exclusive, royalty-bearing license, with the right to sublicense, under certain Company patent rights and know-how to develop and commercialize any pharmaceutical product (the “Product”) containing rigosertib in all uses of rigosertib in humans in Latin American countries (the “Territory,” including Argentina, Belize, Bolivia, Brazil, Chile, Colombia, Costa Rica, Cuba, Dominican Republic, Ecuador, El Salvador, French Guiana, British Guiana, Suriname, Guatemala, Haiti, Honduras, Mexico, Nicaragua, Panama, Paraguay, Peru, Uruguay and Venezuela). Pint agreed to make an upfront equity investment in the Company’s common stock. In addition, the Company could receive up to $41.5 million in additional regulatory, development and sales-based milestone payments, an additional equity investment, as well as tiered, double digit royalties based on net aggregate net sales in the Territory. Pint and the Company have also agreed to enter into a supply agreement providing for Pint purchasing rigosertib and the Product from the Company within 90 days of the FDA approval of an a New Drug Application (“NDA”) for the Product. Pint may terminate the License Agreement in whole (but not in part) at any time upon 45 days’ prior written notice. The License Agreement also contains certain provisions for termination by either party in the event of breach of the License Agreement by the other party, subject to a cure period, or bankruptcy of the other party. Under the terms of the Securities Purchase Agreement, Pint agreed to make an upfront equity investment in the Company at a specified premium to the Company’s share price. Pursuant to the Securities Purchase Agreement, closing of the upfront equity investment occurred on April 4, 2018 and Pint purchased 54,463 shares of common stock for $1,250,000. The total amount of the premium was $319,000 and this amount was allocated to the license. In addition, under the Securities Purchase Agreement, if the FDA approves the NDA for the Product, Pint will reimburse the Company for certain research and development expenses. Half of the reimbursement amount will be paid in cash, the other half of the amount will be by an equity investment at a premium to the average of the volume weighted average price of common stock for the ten consecutive trading days ended on the day the FDA approves the NDA. Pursuant to the Securities Purchase Agreement, the common stock purchased by Pint is subject to certain lock-up restrictions and Pint is entitled to certain registration and participation rights. The Company assessed the Pint arrangement for revenue recognition in accordance with ASC 606 and determined that the license was distinct and that control of the license had been transferred during the second quarter of 2018. As such, the Company recognized the $319,000 allocated to the license in the quarter ended June 30, 2018. HanX Rigosertib Agreement On May 10, 2019, the Company entered into a License and Collaboration Agreement (the “HanX License Agreement”) with HanX and two Securities Purchase Agreements (the “HanX Securities Purchase Agreements”), one with HanX and the other with an affiliate of HanX. Under the terms of the HanX License Agreement, the Company granted HanX an exclusive, royalty-bearing license, with the right to sublicense, to study and commercialize rigosertib in greater China (the “HanX Territory,” including the People’s Republic of China, Hong Kong, Macau and Taiwan). In exchange for these rights, HanX will make upfront payments to the Company totaling $4 million, including a $2.0 million upfront fee and an investment totaling $2.0 million to purchase shares of the Company at a premium to market. HanX will also dedicate $2.0 million in local currency, to be placed in escrow, for clinical development expenses in the HanX Territory. If HanX spends more than $2.0 million in the research and development of rigosertib during the first two years after the effective date of the HanX License Agreement, the Company shall reimburse HanX such excess amount up to a maximum aggregate amount of $0.5 million. In addition, the Company could receive regulatory, development and sales-based milestone payments up to $45.5 million and receive tiered royalties up to double digits on net sales in in the HanX Territory. The Company will also supply rigosertib for sale in the HanX Territory. Unless terminated earlier, the HanX License Agreement will expire upon the expiration of all royalty payment obligations. HanX may terminate the HanX License Agreement in whole (but not in part) at any time upon 45 days’ prior written notice. The HanX License Agreement also contains certain provisions for termination by either party in the event of breach of the HanX License Agreement by the other party, subject to a cure period, or bankruptcy of the other party. Under the terms of the HanX Securities Purchase Agreement, HanX and its affiliate agreed to make upfront equity investments in the Company at a specified premium to the Company’s share price. The common stock purchased by HanX and its affiliates is subject to certain lock-up restrictions and HanX and its affiliates are entitled to certain registration and participation rights. The Company assessed the HanX License Agreement for revenue recognition in accordance with ASC 606 and determined that there are two distinct performance obligations: the license and the supply of rigosertib for sale in the HanX Territory. The Company concluded that control of the license had been transferred to HanX during the three months ended June 30, 2019 and recognized license revenue of $1.7 million, which is net of applicable taxes withheld by the Chinese government, related to the $2.0 million upfront fee. The Company believes a portion of the tax being withheld by the Chinese government may be recoverable at a later date and could be recognized as license revenue if and when recovered by the Company. The $1.7 million was recorded as a receivable at June 30, 2019 and the payment was received in August 2019. Pursuant to the HanX Securities Purchase Agreements, closing of one of the upfront equity investments occurred on May 15, 2019 when an affiliate of HanX purchased 103,520 shares of common stock for $0.5 million. The total amount of the premium was $0.1 million and this amount was recognized as license revenue during the three months ended June 30, 2019. The remaining upfront equity investments represent equity-classified forward contracts for the purchase of the Company’s equity at a pre-determined price. The premium of the future equity purchase from HanX as of the contract date of 0.2 million has been recognized as license revenue during the three months ended June 30, 2019 and included in other current assets at June 30, 2019. On July 9, 2019, the Company extended the deadline for payments under the HanX License Agreement and the HanX Securities Purchase Agreements. On August 8, 2019 Onconova received the non-refundable license fee from HanX. On August 14, 2019, the Company further extended the deadline of HanX’ remaining upfront payments relating to the its equity investment in the Company while HanX continues to seek Chinese regulatory approval for such equity investment. At inception of the HanX License Agreement, it is uncertain as to whether the Company will need to reimburse HanX for all, or a portion, of the $0.5 million excess research and development spending. Therefore, the Company has determined that no liability should be recorded at June 30, 2019, and will reassess this conclusion at each reporting period. In addition, as the development milestones are not within the control of the Company they are not considered probable and revenue will be recognized only upon the achievement of the milestone. The sales milestones and sales-based royalties related to the license will be recognized as revenue as sales occur. For the supply of rigosertib for sale in the HanX Territory, the Company will recognize revenue at a point in time when HanX obtains control of the product, which is typically upon shipment.

Securities Registrations and Sales Agreements	6 Months Ended
Securities Registrations and Sales Agreements	Jun. 30, 2019
Securities Registrations and Sales Agreements
Securities Registrations and Sales Agreements	13. Securities Registrations and Sales Agreements On October 8, 2015, the Company entered into a Purchase Agreement, and a registration rights agreement with Lincoln Park. A registration statement (Form S-1 No. 333-207533), relating to the shares, which was filed with the SEC became effective on November 3, 2015. Subject to the terms and conditions of the purchase agreement, including the effectiveness of a registration statement covering the resale of the shares, the Company may sell additional shares of its Common Stock, having an aggregate offering price of up to $15,000,000 to Lincoln Park from time to time until December 1, 2018. Upon execution of the Lincoln Park purchase agreement, Lincoln Park made an initial purchase of 5,645 shares of the Company’s Common Stock for $1,500,000. Subject to the terms and conditions of the purchase agreement, including the effectiveness of a registration statement covering the resale of the shares, the Company has the right to sell to and Lincoln Park is obligated to purchase up to an additional $15,000,000 of shares of Common Stock, subject to certain limitations, from time to time until December 1, 2018. The Company may direct Lincoln Park, at its sole discretion and subject to certain conditions, to purchase up to 666 shares of Common Stock on any business day, increasing to up to 1,666 shares depending upon the closing sale price of the Common Stock (such purchases, “Regular Purchases”). However, in no event shall a Regular Purchase be more than $1,000,000. The purchase price of shares of Common Stock related to the future funding will be based on the prevailing market prices of such shares at the time of sales. In addition, the Company may direct Lincoln Park to purchase additional amounts as accelerated purchases if on the date of a Regular Purchase the closing sale price of the Common Stock is not below the threshold price as set forth in the Purchase Agreement. The Company’s sales of shares of Common Stock to Lincoln Park under the Purchase Agreement were limited to no more than the number of shares that would result in the beneficial ownership by Lincoln Park and its affiliates, at any single point in time, of more than 4.99% of the then-outstanding shares of the Common Stock, which limit increased to 9.99% on May 1, 2016. Pursuant to the terms of the Lincoln Park purchase agreement and to comply with the listing rules of the Nasdaq Stock Market, the number of shares issued to Lincoln Park thereunder shall not exceed 19.99% of the Company’s shares outstanding on October 8, 2015 unless the approval of the Company’s stockholders is obtained. This limitation shall not apply if the average price paid for all shares issued and sold under the purchase agreement is equal to or greater than $233.40. The Company is not required or permitted to issue any shares of Common Stock under the Lincoln Park purchase agreement if such issuance would breach the Company’s obligations under the listing rules of the Nasdaq Stock Market. As consideration for entering into the purchase agreement, the Company issued to Lincoln Park 1,333 shares of Common Stock. Lincoln Park represented to the Company, among other things, that it was an “accredited investor” (as such term is defined in Rule 501(a) of Regulation D under the Securities Act of 1933, as amended (the “Securities Act”), and the Company sold the securities in reliance upon an exemption from registration contained in Section 4(2) under the Securities Act. The securities sold may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. The net proceeds to the Company under the Lincoln Park purchase agreement will depend on the frequency and prices at which the Company may sell shares of Common Stock to Lincoln Park. The Company expects that the proceeds received from the initial purchase and any additional proceeds from future sales to Lincoln Park will be used to fund the development of the Company’s clinical and preclinical programs, for other research and development activities and for general corporate purposes. On February 8, 2018, the Company entered into an underwriting agreement (the “February 2018 Underwriting Agreement”) with H.C. Wainwright & Co., LLC (“HCW”), relating to the public offering (the “February 2018 Offering”) of 380,500 shares of the Company’s common stock and pre-funded warrants (the “February 2018 Pre-Funded Warrants”) to purchase an aggregate of 196,167 shares of common stock. Each share of common stock or February 2018 Pre-Funded Warrant, as applicable, was sold as a unit with a warrant to purchase Series A Preferred Stock which is convertible to common stock (the “February 2018 Preferred Stock Warrants”). Each February 2018 Preferred Stock Warrant is for one -fifteenth of a share of common stock, on an as converted basis. The combined public offering price was $15.15 per common stock unit or $15.00 per February 2018 Pre-Funded Warrant unit. The Company also granted HCW a 30-day option to purchase up to 86,500 additional shares of common stock at a purchase price of $15.00 per share and February 2018 Preferred Stock Warrants to purchase shares of Series A Preferred Stock convertible into 86,500 shares of common stock at a purchase price of $0.15 per February 2018 Preferred Stock Warrant, less the underwriting discounts and commissions. Prior to closing, HCW exercised this option in full. The offering closed on February 12, 2018. Net proceeds from the offering were approximately $8.7 million after deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the offering to fund the development of its clinical and preclinical programs, for other research and development activities and for general corporate purposes, which may include capital expenditures and funding its working capital needs. The shares of common stock or February 2018 Pre-Funded Warrants, as applicable, and the accompanying February 2018 Preferred Stock Warrants could only be purchased together as a unit in the offering but were issued as separate securities. The February 2018 Pre-Funded Warrants are exercisable immediately at an exercise price of $0.15 per share, may be exercised until they are exercised in full, and may be exercised on a cashless basis in certain circumstances specified therein. The February 2018 Preferred Stock Warrants are exercisable immediately for Series A Preferred Stock at an exercise price of $15.15 per common share, on an as converted basis and will expire on the earlier of (A) the one-month anniversary of the date on which the Company publically releases topline results of the INSPIRE Pivotal phase 3 that compare the overall survival (OS) of patients in the rigosertib group vs the Physician’s Choice group, in all patients and in a subgroup of patients with IPSS-R very high risk and (B) December 31, 2019. The February 2018 Preferred Stock Warrants may be exercised on a cashless basis in certain circumstances specified therein. HCW acted as sole book-running manager for the offering, which was a firm commitment underwritten public offering pursuant to a registration statement on Form S-1 (Registration No. 333-222374) that was declared effective by the SEC on February 7, 2018. The offering was made only by means of a prospectus forming a part of the effective registration statement. The Company paid HCW a commission equal to 7.0% of the gross proceeds of the offering, a management fee equal to 1.0% of the gross proceeds of the offering and other expenses. As additional compensation, the Company issued warrants to HCW exercisable for shares of Series A Preferred Stock, which are convertible into 33,158 shares of common stock subject to the terms of the Series A Preferred Stock. These warrants have substantially the same terms as the February 2018 Preferred Stock Warrants except that the exercise price per share is equal to $18.9375 per share of common stock, on an as converted basis. On September 24, 2018, in exchange for HCW agreement to provide shareholder advisory services to the Company for a period of three months starting on September 24, 2018, the Company repriced these warrants to an exercise price per share equal to $7.96875 per share of common stock, on an as converted basis. On April 27, 2018, the Company entered into an underwriting agreement with HCW relating to the public offering (the “April 2018 Offering”) of 3,105,882 shares of the Company’s common stock and pre-funded warrants (the “May 2018 Pre-Funded Warrants”) to purchase an aggregate of 815,686 shares of common stock. Each share of common stock or May 2018 Pre-Funded Warrant, as applicable, was sold as a unit with a warrant to purchase Series B Preferred Stock which is convertible to common stock (the “May 2018 Preferred Stock Warrants”). Each May 2018 Preferred Stock Warrant is for one-fifteenth of a share of common stock, on an as converted basis. The combined public offering price was $6.375 per common stock unit or $6.225 per May 2018 Pre-Funded Warrant unit. The Company also granted HCW a 30-day option to purchase up to 588,235 additional shares of common stock at a purchase price of $6.225 per share and May 2018 Preferred Stock Warrants to purchase shares of Series B Preferred Stock convertible into 588,235 shares of common stock at a purchase price of $0.15 per May 2018 Preferred Stock Warrant, less the underwriting discounts and commissions. Prior to closing, HCW exercised this option in full. The offering closed on May 1, 2018. Net proceeds from the offering were approximately $25.6 million after deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the offering to fund the development of its clinical and preclinical programs, for other research and development activities and for general corporate purposes, which may include capital expenditures and funding its working capital needs. The shares of common stock or May 2018 Pre-Funded Warrants, as applicable, and the accompanying May 2018 Preferred Stock Warrants could only be purchased together as a unit in the offering but were issued as separate securities. The May 2018 Pre-Funded Warrants are exercisable immediately at an exercise price of $0.15 per share, may be exercised until they are exercised in full, and may be exercised on a cashless basis in certain circumstances. The May 2018 Preferred Stock Warrants are exercisable immediately for Series B Preferred Stock at an exercise price of $6.375 per common share, on an as converted basis and will expire on the 18-month anniversary of June 8, 2018, the date on which the Company publicly announced through the filing of a Current Report on Form 8-K that a Certificate of Amendment to the Company’s Tenth Amended and Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of common stock from 100,000,000 to 250,000,000, was filed with the Secretary of State of the State of Delaware. The May 2018 Preferred Stock Warrants may be exercised on a cashless basis in certain circumstances. HCW acted as sole book-running manager for the offering, which was a firm commitment underwritten public offering pursuant to a registration statement on Form S-1 (Registration No. 333-224315) that was declared effective by the SEC on April 26, 2018. The offering was made only by means of a prospectus forming a part of the effective registration statement. The Company paid HCW a commission equal to 8.0% of the gross proceeds of the offering, a management fee equal to 1.0% of the gross proceeds of the offering and other expenses. In connection with the February 2018 Offering, the Company agreed to certain restrictions (the “Company Lock-Up”) set forth in Section 5(j) of the February 2018 Underwriting Agreement. The Company Lock-Up, among other items, prohibited the Company, during a period of one hundred and thirty-five (135) days from February 8, 2018, without the prior written consent of HCW, from offering or selling any Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock. In order to received HCW’s waiver of the Company Lock-Up, in connection with the April 2018 Offering, on April 16, 2018, the Company entered into a Lock-Up Waiver Agreement (the “Lock-Up Waiver Agreement”) with HCW and certain holders of the February 2018 Preferred Stock Warrants, pursuant to which (i) HCW waived the Company Lock-Up solely with respect to the April 2018 Offering, and (ii) the Company agreed to reduce the exercise price of the February 2018 Preferred Stock Warrants such that the exercise price of the February 2018 Preferred Stock Warrants shall be equal to 105% of the public offering price of common stock sold in the April 2018 Offering (but only to the extent that such public offering price is lower than the current exercise price of the February 2018 Preferred Stock Warrants) and that such repricing shall be effective concurrently with the closing of the April 2018 Offering. This modification of the February 2018 Preferred Stock Warrants was accounted for as an equity issuance cost. In accordance with the Lock-Up Waiver Agreements, the exercise price of the February 2018 Preferred Stock Warrants was repriced from $15.15 per share of common stock, on as converted basis to $6.69375 per share of common stock, on as converted basis, when the April 2018 Offering closed on May 1, 2018.

Summary of Significant Accounting Policies (Policies)	6 Months Ended
Summary of Significant Accounting Policies (Policies)	Jun. 30, 2019
Summary of Significant Accounting Policies
Basis of Presentation	Basis of Presentation The condensed consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States (“GAAP”) for interim financial information. Certain information and footnotes normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). The financial statements include the consolidated accounts of the Company, its wholly-owned subsidiary, Onconova Europe GmbH, and GBO (through the date of its dissolution in June 2018). All significant intercompany transactions have been eliminated.
Unaudited Interim Financial Information	Unaudited Interim Financial Information The accompanying condensed consolidated balance sheet as of June 30, 2019, the condensed consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2019 and 2018, the consolidated statements of stockholders’ (deficit) equity for the three and six months ended June 30, 2019 and 2018 and the condensed consolidated statements of cash flows for the six months ended June 30, 2019 and 2018 are unaudited. The interim unaudited condensed consolidated financial statements have been prepared on the same basis as the annual audited consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the Company’s financial position as of June 30, 2019, the results of its operations for the three and six months ended June 30, 2019 and 2018, and its cash flows for the six months ended June 30, 2019 and 2018. The financial data and other information disclosed in these notes related to the three and six months ended June 30, 2019 and 2018 are unaudited. The results for the three and six months ended June 30, 2019 are not necessarily indicative of results to be expected for the year ending December 31, 2019, any other interim periods, or any future year or period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto for the year ended December 31, 2018 included in the Company’s annual report on Form 10-K filed with the SEC on April 1, 2019. Certain prior year amounts have been reclassified to conform to current period presentation. All common stock, equity, share and per share amounts in the financial statements and notes have been retroactively adjusted to reflect a one-for-fifteen reverse stock split which was effective September 25, 2018.
Segment Information	Segment Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one segment, which is the identification and development of oncology therapeutics.
Significant Accounting Policies	Significant Accounting Policies The Company’s significant accounting policies are disclosed in the audited consolidated financial statements for the year ended December 31, 2018 included in the Company’s annual report on Form 10-K filed with the SEC on April 1, 2019. Since the date of such financial statements, there have been no changes to the Company’s significant accounting policies, with the exception of the adoption of new FASB guidance related to leases.
Fair Value Measurements	Fair Value Measurements The carrying amounts reported in the accompanying consolidated financial statements for cash and cash equivalents, accounts payable, and accrued liabilities approximate their respective fair values because of the short-term nature of these accounts. The fair value of the warrant liability is discussed in Note 7, “Fair Value Measurements.”
Revenue Recognition	Revenue Recognition The Company recognizes revenue in accordance with Accounting Standards Codification Topic 606, Revenue from Contracts with Customers (ASC 606), which the Company adopted effective January 1, 2018 using the modified retrospective method. There was no material impact to our financial position and results of operations as a result of the adoption. The Company applies ASC 606 to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. In accordance with ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that it will collect the consideration it is entitled to in exchange for the goods and services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract that falls under the scope of ASC 606, determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. The Company derives revenue from collaboration and licensing agreements and from the sale of products associated with material transfer, collaboration and supply agreements. License, Collaboration and Other Revenues The Company enters into licensing and collaboration agreements, under which it licenses certain of its product candidates’ rights to third parties. The Company recognizes revenue related to these agreements in accordance with ASC 606. The terms of these arrangements typically include payment from third parties of one or more of the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments; and royalties on net sales of the licensed product. In determining the appropriate amount of revenue to be recognized as it fulfills its obligation under each of its agreements, the Company performs the five steps described above. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement of personnel costs, discount rates and probabilities of technical and regulatory success. Licensing of Intellectual Property: If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other performance obligations, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front-fees. The Company evaluates the measure of progress each reporting period, and, if necessary, adjusts the measure of performance and related revenue recognition. Milestone Payments: At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal will not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensees, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in their period of adjustment. Manufacturing supply services. Arrangements that include a promise for future supply of drug substance or drug product for either clinical development or commercial supply at the customer’s discretion are generally considered as options. The Company assesses if these options provide material rights to the licensee and if so, they are accounted for as separate performance obligations. If the Company is entitled to additional payments when the customer exercises these options, any additional payments are recorded when the customer obtains control of the goods, which is upon shipment. Royalties: For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some of all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue from its license agreements.
Leases	Leases The Company accounts for leases in accordance with Accounting Standards Codification Topic 842, Leases (ASC 842), which the Company adopted effective January 1, 2019. The Company determines whether an arrangement is a lease at contract inception by establishing if the contract conveys the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. Right of Use (ROU) Assets and Lease Liabilities are recognized at the lease commencement date based on the present value of all minimum lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments, when the implicit rate is not readily determinable. Lease terms may include options to extend or terminate the lease. These options are included in the lease term when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has elected the following policy elections on adoption: use of portfolio approach on leases of assets under master service agreements, exclusion of short term leases (term of 12 months or less) on the balance sheet, and not separating lease and non-lease components. At January 1, 2019 and June 30, 2019 the Company had one lease, which was for office space. The lease qualifies for the short term lease exception. Consequently, no ROU Asset or Lease Liability was recorded. The lease payments are being recognized as an expense on a straight-line basis over the lease term. Lease payments for the six months ended June 30, 2019 were $96,000. Remaining payments due under the lease at June 30, 2019 are $129,000.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In February 2016 and through subsequent amendments, the FASB issued guidance which supersedes much of the previous guidance for leases. The new guidance requires lessees to recognize a right-of-use asset and a lease liability on their balance sheets for all the leases with terms greater than twelve months. Based on certain criteria, leases are classified as either financing or operating, with classification affecting the pattern of expense recognition in the income statement. For leases with a term of twelve months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. If a lessee makes this election, it should recognize lease expense for such leases generally on a straight-line basis over the lease term. The guidance was effective for fiscal years beginning after December 15, 2018, and interim periods within those years, with early adoption permitted. In transition, lessees and lessors were permitted to recognize and measure leases at the date of adoption using a modified retrospective approach. The modified retrospective approach includes a number of optional practical expedients primarily focused on leases that commenced before the effective date of the new guidance, including continuing to account for leases that commence before the effective date in accordance with previous guidance, unless the lease is modified. The Company adopted the guidance in ASC 842 effective January 1, 2019 using the modified retrospective method, which does not require the restatement of prior period amounts. There was no impact to the Company’s financial position and results of operations as a result of the adoption. In August 2018, the FASB issued guidance which changes the disclosure requirements for fair value measurement. The guidance amends the disclosure requirements in ASC Topic 820 by adding, changing, or removing certain disclosures. The guidance is effective for fiscal years beginning after December 15, 2019. The Company believes that the adoption of this guidance will not have a material impact on the Company’s consolidated financial statements. The Company is evaluating the impact of the adoption of the standard on its financial statement disclosures. In November 2018, the FASB issued guidance, which clarifies the interaction between ASC Topic 808, Collaborative Arrangements, and ASC Topic 606, Revenue from Contracts with Customers. The guidance, among other items, clarifies that certain transactions between collaborative participants should be accounted for as revenue under Topic 606 when the collaborative arrangement participant is a customer in the context of a unit of account. The guidance is effective for fiscal years beginning after December 15, 2019. The Company is evaluating the impact that the adoption of this guidance will have on the Company’s consolidated financial statements.

Revenue (Tables)

6 Months Ended

Jun. 30, 2019

Revenue

Schedule of recognized revenue under funding, license and collaboration agreements


	Three Months Ended June 30,				Six Months Ended June 30,
	2019		2018		2019		2018

Symbio
Upfront license fee recognition over time	$	56,000	$	113,000	$	113,000	$	227,000
Supplies		1,000		53,000		12,000		53,000

HanX - rigosertib
Upfront license payment		1,965,000		—		1,965,000		—

HanX - ON123300
Upfront license payment		—		—		—		450,000

Pint
Upfront license payment		—		319,000		—		319,000

	$	2,022,000	$	485,000	$	2,090,000	$	1,049,000

Schedule of deferred revenue


	Symbio
	Upfront Payment

Deferred balance at December 31, 2018	$	4,148,000
Recognition to revenue		113,000

Deferred balance at June 30, 2019	$	4,035,000

Warrants (Tables)

6 Months Ended

Jun. 30, 2019

Warrants

Schedule of warrants outstanding and warrant activity


					Balance				Balance
		Exercise		Expiration	Decemeber 31,	Warrants	Warrants	Warrants	June 30,
Description	Classification	Price		Date	2018	Issued	Exercised	Expired	2019

Non-tradable warrants	Liability	$	172.50	July 2021	6,456	—	—	—	6,456
Tradable warrants	Liability	$	73.80	July 2021	212,801	—	—	—	212,801
Non-tradable pre-funded warrants	Equity	$	0.15	July 2023	394	—	—	—	394
Non-tradable warrants	Equity	$	6.69375	*	663,167	—	—	—	663,167
Non-tradable warrants	Equity	$	7.96875	*	33,158	—	—	—	33,158
Non-tradable warrants	Equity	$	14.10	March 2021	5,000	—	—	—	5,000
Non-tradable warrants	Equity	$	21.15	March 2021	8,333	—	—	—	8,333
Non-tradable warrants	Equity	$	7.7895	June 2021	15,000	—	—	—	15,000
Non-tradable pre-funded warrants	Equity	$	0.15	none	86,167	—	(33,333)	—	52,834
Non-tradable warrants	Equity	$	6.375	**	4,432,962	—	—	—	4,432,962
Non-tradable pre-funded warrants	Equity	$	0.15	none	262,068	—	(187,451)	—	74,617

					5,725,506	—	(220,784)	—	5,504,722

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

Balance Sheet Detail (Tables)

6 Months Ended

Jun. 30, 2019

Balance Sheet Detail

Schedule of receivables


	June 30,		December 31,
	2019		2018

Amounts due from HanX	$	1,679,000	$	—
Other		35,000		35,000
	$	1,714,000	$	35,000

Schedule of prepaid expenses and other current assets


	June 30,		December 31,
	2019		2018

Research and development	$	433,000	$	415,000
Premium on future equity purchase from HanX		214,000		—
Manufacturing		33,000		111,000
Insurance		62,000		166,000
Other		91,000		68,000
	$	833,000	$	760,000

Schedule of property and equipment and related accumulated depreciation


	June 30,		December 31,
	2019		2018

Property and equipment	$	2,228,000	$	2,228,000
Accumulated depreciation		(2,227,000)		(2,219,000)
	$	1,000	$	9,000

Schedule of accrued expenses and other current liabilities


	June 30,		December 31,
	2019		2018

Research and development	$	2,103,000	$	2,285,000
Employee compensation		1,510,000		1,650,000
Professional fees		157,000		225,000
Other		—		13,000
	$	3,770,000	$	4,173,000

Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2019

Fair Value Measurements

Schedule of Black-Scholes option pricing model assumptions

The Company estimated the fair value of the non-tradable warrant liability at June 30, 2019, using the Black-Scholes option pricing model with the following weighted-average assumptions:


Risk-free interest rate	1.75	%
Expected volatility	82.96	%
Expected term	2.04 years
Expected dividend yield	0	%

Schedule of financial assets and liabilities measured at fair value on a recurring basis


	Fair Value Measurement as of:
	June 30, 2019								December 31, 2018
	Level 1		Level 2		Level 3		Balance		Level 1		Level 2		Level 3		Balance

Tradable warrants liability	$	571,000	$	—	$	—	$	571,000	$	176,000	$	—	$	—	$	176,000
Non-tradable warrants liability		—		—		—		—		—		—		—		—
Total	$	571,000	$	—	$	—	$	571,000	$	176,000	$	—	$	—	$	176,000

Stock-Based Compensation (Tables)

6 Months Ended

Jun. 30, 2019

Stock-Based Compensation

Schedule of stock-based compensation expense


	Three Months ended June 30,				Six Months ended June 30,
	2019		2018		2019		2018
General and administrative	$	67,000	$	109,000	$	606,000	$	227,000
Research and development		88,000		102,000		199,000		261,000
	$	155,000	$	211,000	$	805,000	$	488,000

Schedule of stock option activity


		Options Outstanding
					Weighted
			Weighted-		Average
	Shares		Average		Remaining	Aggregate
	Available	Number of	Exercise		Contractual	Intrinsic
	for Grant	Shares	Price		Term (in years)	Value
Balance, December 31, 2018	95,264	379,328	$	76.33	9.19	$	0
Authorized	589,500	—
Granted	(10,000)	10,000	$	3.72	9.75
Exercised	—	—	$	—
Forfeitures	23,626	(33,534)	$	61.68	8.92
Balance, June 30, 2019	698,390	355,794	$	75.67	8.70	$	0
Vested or expected to vest, June 30, 2019		346,507	$	192.66	7.93	$	0
Exercisable at June 30, 2019		131,468	$	192.66	7.93	$	0

Schedule of information with respect to stock options outstanding and exercisable

Information with respect to stock options outstanding and exercisable at June 30, 2019 is as follows:


Exercise Price	Shares	Exercisable
$3.41 – $7.05	288,246	71,040
$16.35 – $97.50	48,133	41,090
$222.00 – $225.00	1,871	1,811
$348.00 – $597.00	4,867	4,863
$651.00 – $1,129.50	5,432	5,419
$1,992.00 – $2,268.00	6,910	6,910
$4,156.50 – $4,371.00	335	335
	355,794	131,468

Schedule of weighted-average assumptions used for estimating the fair value of the stock compensation granted


	Six Months ended June 30,
	2019			2018
Risk-free interest rate		1.82	%		2.60	%
Expected volatility		83.68	%		74.13	%
Expected term		6.25	years		5.78	years
Expected dividend yield		0	%		0	%
Weighted average grant date fair value	$	2.68		$	12.60

Nature of Business - Liquidity - Financial Statement Items (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Nature of Business
Net loss	$ (3,561)	$ (4,321)	$ (11,161)	$ (9,411)
Accumulated deficit	393,057		393,057		$ 381,896
Cash and cash equivalents	$ 5,882	$ 29,540	$ 5,882	$ 29,540	$ 16,970	$ 4,024

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

+ Details

Nature of Business - Liquidity - Rights Offering (Details)					1 Months Ended		3 Months Ended
	May 10, 2019 USD ($) security	May 01, 2018 USD ($) shares	Feb. 12, 2018 USD ($) shares	Jul. 29, 2016 shares	Mar. 31, 2019 employee	Feb. 28, 2019 employee	Mar. 31, 2019 USD ($)	Jun. 30, 2019 USD ($)
Sale of Securities
Proceeds from Issuance or Sale of Equity		$ 25,600,000	$ 8,700,000
Workforce Reduction
Number of employees terminated \| employee					6	6
Workforce reduction, number of employees as a percentage of workforce (as a percent)					24.00%	24.00%
Severance related charge							$ 1,843,000
Severance related charge includes non-cash charge							$ 415,000
Accrued severance balance								$ 810,000
Han X
Workforce Reduction
Number of securities purchase Agreements \| security	2
Amount of payment upfront totaling	$ 4,000,000
Paid of upfront payments fees	2,000,000
Amount of purchase shares at premium market	2,000,000
Clinical development expenses	2,000,000
Payments of development and sales-based milestone	$ 45,500,000
Dealer-Manager Agreement, rights offering
Sale of Securities
Issuance of stock (in shares) \| shares		3,694,118	467,000	239,986
Aggregate net proceeds		$ 25,600,000	$ 8,700,000
Pre-funded warrants \| Series A Convertible Preferred Stock
Sale of Securities
Shares of common stock warrants will purchase (in shares) \| shares			696,325
Pre-funded warrants \| Series B Convertible Preferred Stock
Sale of Securities
Shares of common stock warrants will purchase (in shares) \| shares		4,509,804
Pre-funded warrants \| Securities Offering
Sale of Securities
Shares of common stock warrants will purchase (in shares) \| shares		815,686	196,167

Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
Revenue (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Revenue
Revenue	$ 2,022	$ 485	$ 2,090	$ 1,049
Deferred revenue
Balance at the beginning of the period			226
Balance at the end of the period	226		226
Symbio Upfront Payment
Deferred revenue
Balance at the beginning of the period			4,148
Recognition to revenue			113
Balance at the end of the period	4,035		4,035
SymBio \| Symbio Upfront Payment
Revenue
Revenue	56	113	113	227
SymBio \| SymBio clinical supplies
Revenue
Revenue	1	53	12	53
HanX - rigosertib
Revenue
Revenue	1,700
HanX - rigosertib \| Hanx upfront license payment
Revenue
Revenue	$ 1,965		$ 1,965
HanX - ON123300 \| Hanx upfront license payment
Revenue
Revenue				450
Pint
Deferred revenue
Recognition to revenue		319
Pint \| Pint upfront license payment
Revenue
Revenue		$ 319		$ 319

Warrants (Details) - $ / shares	6 Months Ended
Warrants (Details) - $ / shares	Jun. 30, 2019	Dec. 31, 2018	Jun. 07, 2018	Jun. 06, 2018	Mar. 21, 2018	Mar. 20, 2018
Warrants outstanding and warrant activity
Balance at beginning of the period (in shares)	5,725,506
Warrants Exercised (in shares)	(220,784)
Balance at end of the period (in shares)	5,504,722
Common Stock authorized (in shares)	250,000,000	250,000,000	250,000,000	100,000,000	100,000,000	25,000,000
Non-tradable warrants expiring July 2021, Liability
Warrants
Warrant exercise price (in dollars per share)	$ 172.50
Warrants outstanding and warrant activity
Balance at beginning of the period (in shares)	6,456
Balance at end of the period (in shares)	6,456
Tradable warrants expiring July 2021, Liability
Warrants
Warrant exercise price (in dollars per share)	$ 73.80
Warrants outstanding and warrant activity
Balance at beginning of the period (in shares)	212,801
Balance at end of the period (in shares)	212,801
Non-tradable pre-funded warrants expiring July 2023, Equity
Warrants
Warrant exercise price (in dollars per share)	$ 0.15
Warrants outstanding and warrant activity
Balance at beginning of the period (in shares)	394
Balance at end of the period (in shares)	394
Non-tradable warrants with exercise price 6.69375 Equity
Warrants
Warrant exercise price (in dollars per share)	$ 6.69375
Warrants outstanding and warrant activity
Balance at beginning of the period (in shares)	663,167
Balance at end of the period (in shares)	663,167
Non-tradable warrants with exercise price 7.96875 Equity
Warrants
Warrant exercise price (in dollars per share)	$ 7.96875
Warrants outstanding and warrant activity
Balance at beginning of the period (in shares)	33,158
Balance at end of the period (in shares)	33,158
Non-tradable warrants with exercise price 14.10 Equity
Warrants
Warrant exercise price (in dollars per share)	$ 14.10
Warrants outstanding and warrant activity
Balance at beginning of the period (in shares)	5,000
Balance at end of the period (in shares)	5,000
Non-tradable warrants with exercise price 21.15 Equity
Warrants
Warrant exercise price (in dollars per share)	$ 21.15
Warrants outstanding and warrant activity
Balance at beginning of the period (in shares)	8,333
Balance at end of the period (in shares)	8,333
Non-tradable warrants with exercise price 7.7895 Equity
Warrants
Warrant exercise price (in dollars per share)	$ 7.7895
Warrants outstanding and warrant activity
Balance at beginning of the period (in shares)	15,000
Balance at end of the period (in shares)	15,000
Non-tradable pre-funded warrants with exercise Price 0.15 Equity
Warrants
Warrant exercise price (in dollars per share)	$ 0.15
Warrants outstanding and warrant activity
Balance at beginning of the period (in shares)	86,167
Warrants Exercised (in shares)	(33,333)
Balance at end of the period (in shares)	52,834
Non-tradable warrants with exercise price 6.375 Equity
Warrants
Warrant exercise price (in dollars per share)	$ 6.375
Warrants outstanding and warrant activity
Balance at beginning of the period (in shares)	4,432,962
Balance at end of the period (in shares)	4,432,962
Non-tradable warrants with exercise price 0.15 Equity1
Warrants
Warrant exercise price (in dollars per share)	$ 0.15
Warrants outstanding and warrant activity
Balance at beginning of the period (in shares)	262,068
Warrants Exercised (in shares)	(187,451)
Balance at end of the period (in shares)	74,617

Fair Value Measurements - Rights Offering (Details) - Dealer-Manager Agreement, rights offering - $ / shares	May 01, 2018	Feb. 12, 2018	Jul. 29, 2016
Sale of Securities
Issuance of stock (in shares)	3,694,118	467,000	239,986
Tradable warrants liability
Sale of Securities
Rights or warrants issued (in shares)			212,801
Exercisable, term (in years)			5 years
Shares into which each warrant can be converted (in shares)			1
Exercise price (in dollars per share)			$ 73.80
Redemption period (in years)			1 year
Redemption price (in dollars per share)			$ 0.001
Volume weighted average price per share of common stock (in dollars per share)			$ 184.50
Threshold consecutive trading days (in days)			10 days
Pre-funded warrants
Sale of Securities
Rights or warrants issued (in shares)			43,760

Stock-Based Compensation - Summary of Stock Option Activity (Details) - Stock options - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Shares Available for Grant
Balance at the beginning of the period (in shares)	95,264
Authorized (in shares)	589,500
Granted (in shares)	10,000
Forfeitures (in shares)	23,626
Balance at the end of the period (in shares)	698,390	95,264
Number of Shares
Balance at the beginning of the period (in shares)	379,328
Granted (in shares)	10,000
Forfeitures (in shares)	(33,534)
Balance at the end of the period (in shares)	355,794	379,328
Vested or expected to vest at the end of the period (in shares)	346,507
Exercisable at the end of the period (in shares)	131,468
Weighted-Average Exercise Price
Balance at the beginning of the period (in dollars per share)	$ 76.33
Granted (in dollars per share)	3.72
Forfeitures (in dollars per share)	61.68
Balance at the end of the period (in dollars per share)	75.67	$ 76.33
Vested or expected to vest at the end of the period (in dollars per share)	192.66
Exercisable at the end of the period (in dollars per share)	$ 192.66
Additional Disclosures
Weighted average remaining contractual term	8 years 8 months 12 days	9 years 2 months 9 days
Weighted average remaining contractual term of options forfeitures	8 years 11 months 1 day
Weighted average remaining contractual term of options vested or expected to vest	7 years 11 months 5 days
Weighted average remaining contractual term of options exercisable	7 years 11 months 5 days
Aggregate intrinsic value of options outstanding	$ 0	$ 0
Aggregate intrinsic value of options vested or expected to vest	0
Aggregate intrinsic value of options exercisable	$ 0

Stock-Based Compensation - Stock Options Outstanding and Exercisable (Details) - Stock options	6 Months Ended
	Jun. 30, 2019 $ / shares shares
Share-Based Compensation
Shares (in shares)	355,794
Exercisable (in shares)	131,468
Exercise Price Range $3.41 - $7.05
Share-Based Compensation
Exercise price, lower range limit (in dollars per share) \| $ / shares	$ 3.41
Exercise price, upper range limit (in dollars per share) \| $ / shares	$ 7.05
Shares (in shares)	288,246
Exercisable (in shares)	71,040
Exercise Price Range $16.35 - $97.50
Share-Based Compensation
Exercise price, lower range limit (in dollars per share) \| $ / shares	$ 16.35
Exercise price, upper range limit (in dollars per share) \| $ / shares	$ 97.50
Shares (in shares)	48,133
Exercisable (in shares)	41,090
Exercise Price Range $222.00 - $225.00
Share-Based Compensation
Exercise price, lower range limit (in dollars per share) \| $ / shares	$ 222.00
Exercise price, upper range limit (in dollars per share) \| $ / shares	$ 225.00
Shares (in shares)	1,871
Exercisable (in shares)	1,811
Exercise Price Range $348.00 - $597.00
Share-Based Compensation
Exercise price, lower range limit (in dollars per share) \| $ / shares	$ 348.00
Exercise price, upper range limit (in dollars per share) \| $ / shares	$ 597.00
Shares (in shares)	4,867
Exercisable (in shares)	4,863
Exercise Price Range $651.00 - $1,129.50
Share-Based Compensation
Exercise price, lower range limit (in dollars per share) \| $ / shares	$ 651.00
Exercise price, upper range limit (in dollars per share) \| $ / shares	$ 1,129.50
Shares (in shares)	5,432
Exercisable (in shares)	5,419
Exercise Price Range $1,992.00 - $2,268.00
Share-Based Compensation
Exercise price, lower range limit (in dollars per share) \| $ / shares	$ 1,992.00
Exercise price, upper range limit (in dollars per share) \| $ / shares	$ 2,268.00
Shares (in shares)	6,910
Exercisable (in shares)	6,910
Exercise Price Range $4,156.50 - $4,371.00
Share-Based Compensation
Exercise price, lower range limit (in dollars per share) \| $ / shares	$ 4,156.50
Exercise price, upper range limit (in dollars per share) \| $ / shares	$ 4,371.00
Shares (in shares)	335
Exercisable (in shares)	335

License and Collaboration Agreements (Details) - USD ($)					1 Months Ended		3 Months Ended			6 Months Ended
	May 15, 2019	May 10, 2019	Apr. 11, 2018	Mar. 02, 2018	Jan. 31, 2018	Jul. 31, 2011	Jun. 30, 2019	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018
License and collaboration agreements
Revenue							$ 2,022,000	$ 485,000		$ 2,090,000	$ 1,049,000
Value of stock issued							392,000			392,000
Research and development							3,895,000	4,070,000		7,969,000	8,647,000
License revenue							2,022,000	485,000		2,090,000	$ 1,049,000
Pint
License and collaboration agreements
Recognition to revenue								$ 319,000
HanX - rigosertib
License and collaboration agreements
Upfront payment received		$ 4,000,000
Revenue							1,700,000
Issuance of stock (in shares)	103,520
Value of stock issued	$ 500,000
Amount of premium							100,000
Paid of upfront payments fees		2,000,000					2,000,000			2,000,000
Amount of purchase shares at premium market		2,000,000
Clinical development expenses		2,000,000
Payments of development and sales-based milestone		45,500,000
Research and development		2,000,000
License revenue							1,700,000
License revenue receivable							$ 1,700,000			$ 1,700,000
Maximum aggregate amount		500,000
Common Stock
License and collaboration agreements
Issuance of stock (in shares)							103,520			103,520
Value of stock issued							$ 1,000			$ 1,000
HanX license payment \| HanX - rigosertib
License and collaboration agreements
Research and development		$ 500,000
License agreement \| SymBio
License and collaboration agreements
Percentage of discount on future purchases					35.00%
License agreement \| SymBio \| Maximum
License and collaboration agreements
Cumulative amount of discount on purchases					$ 300,000
License agreement \| HanX - ON123300
License and collaboration agreements
Upfront payment received			$ 450,000
License agreement \| Rigosertib \| SymBio
License and collaboration agreements
Upfront payment received						$ 7,500,000
Aggregate milestone payments						22,000,000
Aggregate potential milestone payments based on annual net sales						$ 30,000,000
Percentage of royalty payments based on net sales of rigosertib (as a percent)						20.00%
License agreement \| Rigosertib \| Pint
License and collaboration agreements
Aggregate potential milestone payments based on annual net sales				$ 41,500,000
Prior written notice period for termination (in days)				45 days
License and collaboration \| HanX license payment \| HanX - ON123300
License and collaboration agreements
Revenue									$ 450,000
License revenue									$ 450,000
Securities Purchase Agreement \| Common Stock \| Pint
License and collaboration agreements
Issuance of stock (in shares)				54,463
Value of stock issued				$ 1,250,000
Amount of premium				$ 319,000
United States and Japan \| License agreement \| Rigosertib \| SymBio
License and collaboration agreements
Aggregate milestone payments due upon receipt of marketing approval for an additional indication						$ 4,000,000
United States \| License agreement \| Rigosertib \| SymBio \| MDS IV indication
License and collaboration agreements
Regulatory milestones payments due upon receipt of marketing approval for indication						5,000,000
United States \| License agreement \| Rigosertib \| SymBio \| Rigosertib oral in lower risk MDS patients
License and collaboration agreements
Regulatory milestones payments due upon receipt of marketing approval for indication						5,000,000
Japan \| License agreement \| Rigosertib \| SymBio \| MDS IV indication
License and collaboration agreements
Regulatory milestones payments due upon receipt of marketing approval for indication						3,000,000
Japan \| License agreement \| Rigosertib \| SymBio \| Rigosertib oral in lower risk MDS patients
License and collaboration agreements
Regulatory milestones payments due upon receipt of marketing approval for indication						$ 5,000,000

Preclinical Collaboration / Non-controlling Interest (Details) $ in Thousands	1 Months Ended	3 Months Ended	6 Months Ended	12 Months Ended
	Nov. 30, 2014 USD ($)	Jun. 30, 2018 USD ($) Program	Jun. 30, 2018 USD ($) Program	Dec. 31, 2013 USD ($) Program	Dec. 31, 2012 Program
Preclinical Collaboration
Gain on dissolution of GBO		$ 693	$ 693
Non-controlling interest portion upon consolidation		$ (163)	$ (163)
GBO
Preclinical Collaboration
Number of new programs to be collaborated and developed \| Program		2	2		2
Ownership interest in the joint venture (as a percent)				90.00%
GBO \| GVK BIO
Preclinical Collaboration
Number of new programs to be collaborated and developed \| Program				2
Initial capital contribution				$ 500
Ownership interest in the joint venture (as a percent)	17.50%			10.00%
Additional capital contributions	$ 500
GBO \| GVK BIO \| Minimum
Preclinical Collaboration
Ownership interest in the joint venture (as a percent)				10.00%
GBO \| GVK BIO \| Maximum
Preclinical Collaboration
Ownership interest in the joint venture (as a percent)				50.00%

Securities Registrations and Sales Agreements - Sales and Purchase Agreements (Details) - USD ($) $ / shares in Units, $ in Thousands		12 Months Ended
	Oct. 08, 2015	Dec. 31, 2016
Securities Registrations and Sales Agreement
Aggregate offering price		$ 24,900
Lincoln Park \| Purchase agreement
Securities Registrations and Sales Agreement
Aggregate offering price	$ 15,000
Issuance of stock (in shares)	5,645
Net proceeds from sales of common stock	$ 1,500
Business day limit (in shares)	666
Business day limit contingent upon the closing price of the stock (in shares)	1,666
Regular purchase, one day limit	$ 1,000
Beneficial ownership percentage (as a percent)	4.99%
Beneficial ownership percentage after 180 days (as a percent)	9.99%
Maximum shares issued as a percentage of shares outstanding (as a percent)	19.99%
Minimum average price per share (in dollars per share)	$ 233.40
Stock issued as consideration (in shares)	1,333

Securities Registrations and Sales Agreements - underwriting agreement with HCW (Details) - USD ($) $ / shares in Units, $ in Millions								3 Months Ended	6 Months Ended
	May 01, 2018	Apr. 27, 2018	Apr. 16, 2018	Feb. 12, 2018	Feb. 08, 2018	Nov. 14, 2017	Apr. 26, 2017	Jun. 30, 2019	Jun. 30, 2019	Dec. 31, 2018	Sep. 24, 2018	Jun. 07, 2018	Jun. 06, 2018	Apr. 26, 2018	Mar. 21, 2018	Mar. 20, 2018	May 31, 2017
Subsidiary, Sale of Stock [Line Items]
Net proceeds from stock offering	$ 25.6			$ 8.7
Common Stock authorized (in shares)								250,000,000	250,000,000	250,000,000		250,000,000	100,000,000		100,000,000	25,000,000
Percentage of exercise price of warrants			105.00%
Common Stock
Subsidiary, Sale of Stock [Line Items]
Issuance of stock (in shares)								103,520	103,520
Pre-funded warrants
Subsidiary, Sale of Stock [Line Items]
Warrant exercise price (in dollars per share)					$ 0.15												$ 0.15
Preferred stock warrants
Subsidiary, Sale of Stock [Line Items]
Number of securities converted from warrants as compensation	0.6667				0.0667
Preferred stock warrants \| Series B Convertible Preferred Stock
Subsidiary, Sale of Stock [Line Items]
Warrant exercise price (in dollars per share)																	$ 6.375
Preferred stock warrants \| Common Stock
Subsidiary, Sale of Stock [Line Items]
Warrant exercise price (in dollars per share)	$ 6.69375				$ 15.15
HCW
Subsidiary, Sale of Stock [Line Items]
Underwriters commission (in percentage)					7.00%									8.00%
Management fee (in percentage)					1.00%									1.00%
HCW \| Common Stock
Subsidiary, Sale of Stock [Line Items]
Number of common stock shares for conversion preferred stock received as compensation					33,158
HCW \| Preferred stock warrants \| Common Stock
Subsidiary, Sale of Stock [Line Items]
Warrants exercise price received as compensation (in dollars per share)					$ 18.9375						$ 7.96875
The Offering
Subsidiary, Sale of Stock [Line Items]
Issuance of stock (in shares)						61,333	165,079
The Offering \| Common Stock
Subsidiary, Sale of Stock [Line Items]
Issuance of stock (in shares)		3,105,882			380,500
Share price (in dollars per share)		$ 6.375			$ 15.15
The Offering \| Pre-funded warrants
Subsidiary, Sale of Stock [Line Items]
Warrant purchase price (in dollars per share)					$ 15.00
The Offering \| Pre-funded warrants \| Common Stock
Subsidiary, Sale of Stock [Line Items]
Number of securities to each class of warrant (in shares)		815,686			196,167
Underwriter's option \| HCW
Subsidiary, Sale of Stock [Line Items]
Period available to underwriters to purchase additional shares under the offering					30 days
Underwriter's option \| HCW \| Common Stock
Subsidiary, Sale of Stock [Line Items]
Issuance of stock (in shares)		588,235			86,500
Share price (in dollars per share)		$ 6.225			$ 15.00
Lock-up period for purchased shares by counterparty (in days)					135 days
Underwriter's option \| HCW \| Preferred stock warrants \| Common Stock
Subsidiary, Sale of Stock [Line Items]
Number of securities to each class of warrant (in shares)		588,235			86,500
Warrant purchase price (in dollars per share)		$ 0.15			$ 0.15

Research Agreements	6 Months Ended
Research Agreements	Jun. 30, 2019
Research Agreements
Research Agreements	9. Research Agreements The Company has entered into various licensing and right-to-sublicense agreements with educational institutions for the exclusive use of patents and patent applications, as well as any patents that may develop from research being conducted by such educational institutions in the field of anticancer therapy, genes and proteins. Results from this research have been licensed to the Company pursuant to these agreements. Under one of these agreements with Temple University (“Temple”), the Company is required to make annual maintenance payments to Temple and royalty payments based upon a percentage of sales generated from any products covered by the licensed patents, with minimum specified royalty payments. As no sales had been generated through June 30, 2019 under the licensed patents, the Company has not incurred any royalty expenses related to this agreement. In addition, the Company is required to pay Temple a percentage of any sublicensing fees received by the Company.

Preclinical Collaboration / Non-controlling Interest	6 Months Ended
Preclinical Collaboration / Non-controlling Interest	Jun. 30, 2019
Preclinical Collaboration / Non-controlling Interest
Preclinical Collaboration / Non-controlling Interest	11. Preclinical Collaboration / Non-controlling Interest In December 2012, the Company agreed to form GBO, an entity owned by the Company and GVK. The purpose of GBO was to collaborate on and develop two programs through filing of an investigational new drug application and/or conducting proof of concept studies using the Company's technology platform. During 2013, GVK made an initial capital contribution of $500,000 in exchange for a 10% interest in GBO, and the Company made an initial capital contribution of a sublicense to all the intellectual property controlled by the Company related to the two specified programs in exchange for a 90% interest. Under the terms of the agreement, GVK made additional capital contributions. The GVK percentage interest in GBO could have changed from the initial 10% to up to 50%, depending on the amount of its total capital contributions. During November 2014, GVK made an additional capital contribution of $500,000 which increased its interest in GBO to 17.5%. The Company evaluated its variable interests in GBO on a quarterly basis and determined that it was the primary beneficiary. GBO was reflected in the Company’s financial statements as a non-controlling interest. The two preclinical programs sublicensed to GBO were not developed to clinical stage as initially hoped, and GBO was dissolved in June 2018. The dissolution resulted in a gain of $693,000 to the Company, primarily as a result of forgiveness of GBO payables to GVK . Upon consolidation of GBO, the $693,000 gain and $(163,000) non-controlling interest portion were recorded by the Company in the quarter ended June 30, 2018.

Related-Party Transactions	6 Months Ended
Related-Party Transactions	Jun. 30, 2019
Related-Party Transactions
Related-Party Transactions	12. Related-Party Transactions The Company has entered into a research agreement, as subsequently amended, with the Mount Sinai School of Medicine ("Mount Sinai"), with which a member of its board of directors and a stockholder is affiliated. Mount Sinai is undertaking research on behalf of the Company on the terms set forth in the agreements. Mount Sinai, in collaboration with the Company, will prepare applications for patents generated from the research. Results from all projects will belong exclusively to Mount Sinai, but the Company will have an exclusive option to license any inventions, resulting therefrom. Payments to Mount Sinai under this research agreement for the three months ended June 30, 2019 and 2018 were $88,000 and $88,000, respectively, and for the six months ended June 30, 2019 and 2018 were $175,000 and $175,000, respectively. At June 30, 2019 and December 31, 2018, the Company had $0 and $88,000, respectively, payable to Mount Sinai under this agreement. The Company has entered into a consulting agreement with a member of its board of directors, who is also a significant stockholder of the Company. The board member provides consulting services to the Company on the terms set forth in the agreement. Payments to this board member for both the three months ended June 30, 2019 and 2018 were $33,000, and for both the six months ended June 30, 2019 and 2018 were $66,000 . At both June 30, 2019 and December 31, 2018, the Company had $33,000 payable under this agreement.

Subsequent Event	6 Months Ended
Subsequent Event	Jun. 30, 2019
Subsequent Event
Subsequent Event	14. Subsequent Event On July 9, 2019, the Company extended the deadline for payments under the HanX License Agreement and the HanX Securities Purchase Agreements. On August 8, 2019 Onconova received the non-refundable license fee from HanX. On August 14, 2019, the Company further extended the deadline of HanX’ remaining upfront payments relating to the its equity investment in the Company while HanX continues to seek Chinese regulatory approval for such equity investment.

Nature of Business - Reverse Stock Split (Details)	Sep. 25, 2018
Nature of Business
Reverse stock split ratio	0.067

Nature of Business - The Company - Clinical-stage Product Candidates (Details)	Jun. 30, 2019 item
Nature of Business
Number of clinical-stage product candidates	3

Nature of Business - The Company (Details)	Sep. 25, 2018	Jun. 30, 2019 $ / shares shares	Dec. 31, 2018 $ / shares shares	Jun. 07, 2018 $ / shares shares	Jun. 06, 2018 shares	Mar. 21, 2018 $ / shares shares	Mar. 20, 2018 shares
Nature of Business
Common Stock authorized (in shares) \| shares		250,000,000	250,000,000	250,000,000	100,000,000	100,000,000	25,000,000
Common stock, par value (in dollars per share) \| $ / shares		$ 0.01	$ 0.01	$ 0.01		$ 0.01
Reverse stock split ratio	0.067

Nature of Business - Liquidity - Sale of Stock (Details) - USD ($) $ / shares in Units, $ in Thousands		12 Months Ended
	Jul. 30, 2013	Dec. 31, 2016
Sale of Securities
Aggregate offering price		$ 24,900
IPO
Sale of Securities
Issuance of stock (in shares)	39,611
Price per share (in dollars per share)	$ 2,250.00
Proceeds from initial public offering of common stock, net of issuance costs	$ 79,811

Summary of Significant Accounting Policies - Segment Information (Details)	6 Months Ended
	Jun. 30, 2019 USD ($) segment	Jan. 01, 2019 USD ($)
Segment Information
Number of operating segments \| segment	1
Amount of right of use asset	$ 0	$ 0
Amount of lease liabilities	0	$ 0
Amount of lease payments	96,000
Remaining lease payments	$ 129,000

Net Loss Per Share of Common Stock (Details) - shares	6 Months Ended
Net Loss Per Share of Common Stock (Details) - shares	Jun. 30, 2019	Jun. 30, 2018
Potentially dilutive securities outstanding excluded from the computation of diluted weighted average shares as they would be antidilutive
Potentially dilutive securities outstanding excluded from the computation of diluted weighted average shares	5,860,516	5,798,161
Warrants
Potentially dilutive securities outstanding excluded from the computation of diluted weighted average shares as they would be antidilutive
Potentially dilutive securities outstanding excluded from the computation of diluted weighted average shares	5,504,722	5,725,506
Stock options
Potentially dilutive securities outstanding excluded from the computation of diluted weighted average shares as they would be antidilutive
Potentially dilutive securities outstanding excluded from the computation of diluted weighted average shares	355,794	72,655

Balance Sheet Detail - Receivables (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Receivables:
Other	$ 35	$ 35
Receivables	1,714	$ 35
HanX
Receivables:
Amounts due from HanX	$ 1,679

Balance Sheet Detail - Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Prepaid expenses and other current assets:
Research and development	$ 433	$ 415
Premium on future equity purchase from HanX	214
Manufacturing	33	111
Insurance	62	166
Other	91	68
Total	$ 833	$ 760

Balance Sheet Detail - Property and Equipment (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Property and equipment:
Property and equipment, gross	$ 2,228	$ 2,228
Accumulated depreciation	(2,227)	(2,219)
Property and equipment, net	$ 1	$ 9

Balance Sheet Detail - Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Accrued expenses and other current liabilities:
Research and development	$ 2,103	$ 2,285
Employee compensation	1,510	1,650
Professional fees	157	225
Other		13
Total	$ 3,770	$ 4,173

Fair Value Measurements - Securities Purchase Agreement (Details) - Securities Purchase Agreement $ / shares in Units, $ in Thousands	Jan. 05, 2016 USD ($) $ / shares shares
Sale of Securities
Issuance of stock (in shares)	12,912
Share price (in dollars per share) \| $ / shares	$ 142.50
Aggregate gross proceeds \| $	$ 1,840
Common Stock Warrants
Sale of Securities
Shares of common stock warrants will purchase (in shares)	6,456

Fair Value Measurements - Fair Value Assumptions (Details)	Jun. 30, 2019 Y
Risk-free interest rate
Assumption used to estimate the fair value of warrant liability by utilizing the Black-Scholes option pricing model
Non-tradable warrant liability	1.75
Expected volatility
Assumption used to estimate the fair value of warrant liability by utilizing the Black-Scholes option pricing model
Non-tradable warrant liability	82.96
Expected term
Assumption used to estimate the fair value of warrant liability by utilizing the Black-Scholes option pricing model
Non-tradable warrant liability	2.04
Expected dividend yield
Assumption used to estimate the fair value of warrant liability by utilizing the Black-Scholes option pricing model
Non-tradable warrant liability	0

Fair Value Measurements - Fair Value Hierarchy Table (Details) - Recurring basis - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Liabilities measured at fair value
Total	$ 571	$ 176
Tradable warrants liability
Liabilities measured at fair value
Warrant liability	571	176
Level 1
Liabilities measured at fair value
Total	571	176
Level 1 \| Tradable warrants liability
Liabilities measured at fair value
Warrant liability	$ 571	$ 176

Fair Value Measurements - Transfers (Details) $ in Thousands	Jun. 30, 2019 USD ($)
Fair Value Measurements
Amount of transfers of assets out of Level 1 into Level 2	$ 0
Amount of transfers of assets out of Level 2 into Level 1	0
Amount of transfers of liabilities out of Level 1 into Level 2	0
Amount of transfers of liabilities out of Level 2 into Level 1	$ 0

Stock-Based Compensation - Common Stock Reserved for Issuance and Shares Available for Future Issuance (Details) - Stock options - shares	Jun. 30, 2019	Dec. 31, 2018	Jul. 31, 2013
Stock-Based Compensation
Common Stock available for future issuance (in shares)	698,390	95,264
2013 Plan
Stock-Based Compensation
Common Stock reserved for issuance (in shares)			610,783
Evergreen provision, percentage of issued and outstanding common stock (as a percent)			4.00%
Evergreen provision, shares (in shares)			200,000
2018 Plan
Stock-Based Compensation
Common Stock reserved for issuance (in shares)	35,316
Maximum aggregate number of shares that may be issued under the plan	6,035,316
Common Stock available for future issuance (in shares)	698,390
2018 Plan \| Common Stock
Stock-Based Compensation
Maximum aggregate number of shares that may be issued under the plan	6,000,000
2018 Amended Plan
Stock-Based Compensation
Maximum aggregate number of shares that may be issued under the plan	589,500

Stock-Based Compensation - Unrecognized Compensation Expense (Details) - Options granted after April 23, 2013 - Stock options $ in Thousands	6 Months Ended
	Jun. 30, 2019 USD ($)
Stock-Based Compensation
Unrecognized compensation expense related to unvested stock options	$ 793
Weighted-average period for recognizing unrecognized compensation expense related to unvested stock options (in years)	2 years 3 months 26 days

Stock-Based Compensation - Fair Value Assumptions (Details) - Options granted after April 23, 2013 - Stock options - $ / shares	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Assumptions used
Risk-free interest rate (as a percent)	1.82%	2.60%
Expected volatility (as a percent)	83.68%	74.13%
Expected term (in years)	6 years 3 months	5 years 9 months 11 days
Expected dividend yield (as a percent)	0.00%	0.00%
Weighted average grant date fair value (in dollars per share)	$ 2.68	$ 12.60
Annualized forfeiture rate (as a percent)	4.14%	4.14%

Research Agreements (Details) $ in Thousands	6 Months Ended
Research Agreements (Details) $ in Thousands	Jun. 30, 2019 USD ($)
Temple
Research Agreements
Sales generated from products covered by the licensed patents	$ 0